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Abstract 
Colon cancer is a leading cause of cancer related deaths worldwide. Lifestyle factors such as 
diet and exercise have been implicated as important agents in colon cancer development 
and progression. Epidemiological, in vivo and in vitro studies have found that n-3 
polyunsaturated fatty acids (PUFAs) reduce colon carcinoma. The role of n-6 PUFAs remains 
a controversial topic, with studies indicating both promoting and preventing capabilities 
published. In order to better understand the effects of PUFAs on colon carcinoma, it is 
important to have an understanding of how they will be broken down in the body. During 
this study, in silico metabolism of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) 
and arachidonic acid (AA) predicted the formation of hydroxy-, di-hydroxy- and epoxy-FAs. A 
gas chromatography-mass spectrometry method was developed and validated for the 
detection of these PUFAs and their cytochrome P450 (CYP) metabolites. A human liver 
microsomal system for the in vitro metabolism of EPA, DHA and AA was optimised in terms 
of microsomal and PUFA concentration. The system resulted in the metabolism of the 
positive control, lauric acid, to 12-hydroxy-lauric acid but was unable to metabolise the 
PUFAs of interest. EPA, DHA and AA reduced cell viability in the colon carcinoma cell lines 
SW480 and SW620 in the micromolar concentration range (25 – 200 μM). The CYP 
epoxidation metabolite of EPA, 17, 18-epoxyeicosatetraenoic acid (17, 18-EpETE) resulted in 
a significant reduction in SW480 cell viability relative to the parent compound at lower 
concentrations (25 and 50 μM). Annexin V apoptosis analysis revealed that EPA and 17, 18-
EpETE did not result in apoptosis in SW480 cells at a concentration of 25 μM and over an 
incubation period of 24 hours. A significant reduction in reactive oxygen species production 
was seen in SW480 cells after incubation with 25 μM 17, 18-EpETE for 24 hours. EPA and 17, 
18-EpETE were implicated in the reduction of colon cancer metastasis since they were able 
to reduce SW480 migration and anchorage independent cell growth. These results indicate 
that the dietary intake of EPA, DHA and AA may be beneficial to one’s health due to the 
negative effects that these PUFAs had on colon carcinoma. Future studies are needed to 
confirm these benefits and compare the effects of the PUFAs to their CYP-metabolites. 
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Chapter 1 
Literature Review 
1.1 Introduction 
A link between diet and cancer has been proposed (Bartsch et al., 1999; Milner, 2004), with 
polyunsaturated fatty acids (PUFAs) being implicated as bioactive food components (Bartsch 
et al., 1999; Schley et al., 2005; Bougnoux et al., 2010). Optimizing the intake of specific 
foods and/or their bioactive components, such as PUFAs, may be a practical, noninvasive, 
and cost-effective strategy for reducing the incidence of cancer (Milner, 2004). However, 
this solution is not a simple one since the complexity of the diet and the heterogeneity of 
carcinogenesis make it difficult to establish true interrelationships (Milner, 2004). The 
response to bioactive food components is highly dependent on a number of cellular events 
and regulatory processes, including metabolism (Milner, 2004). Hence it is important to 
understand how PUFAs are broken down in the body and how this metabolism will impact 
their effectiveness. Whilst epidemiological studies are helpful in identifying food 
components that may reduce the incidence of cancer, their results are often highly variable 
due to the considerable variation in the concentration of bioactive components that occur 
in a particular food (Milner, 2004). For this reason, in vitro studies are a helpful tool for 
identifying the effects of bioactive food components on carcinogenesis and the level of 
exposure required in order for these effects to be beneficial.  
 
1.2 Cancer 
1.2.1 Cancer overview 
Cancer is a major health problem in many parts of the world (Jemal et al., 2010). The 
National Cancer Registry (NCR) reported 27 392 new cases of cancer in males and 28 161 
new cases of cancer in females in South Africa in 2004. Over 100 types of cancer have been 
identified, each one having different causes and symptoms (Almeida and Barry, 2010). 
Cancer is divided into four major types: carcinomas, sarcomas, leukemias, and lymphomas 
(Almeida and Barry, 2010). Carcinomas account for about 90% of human cancers, and they 
arise from the epithelium of internal organs, glands and body cavities (Almeida and Barry, 
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2010). Breast, colorectal, lung, prostate, and skin tissues often give rise to carcinomas 
(Almeida and Barry, 2010). Sarcomas are less common than carcinomas, and they are 
formed in connective tissue such as cartilage and bone (Almeida and Barry, 2010). 
Lymphomas and leukemias do not form solid tumors (Almeida and Barry, 2010). 
Lymphomas are cancers of the lymphatic system whilst leukemias are cancers of the bone 
marrow which lead to overproduction and early release of immature leukocytes (Almeida 
and Barry, 2010; Kim et al., 2010).  
 
1.2.2 Cancer cell physiology 
A balance between cell proliferation and cell death exists in the human body such that the 
total number of cells remains relatively constant (Bertram, 2001). Factors altering this 
balance may potentially alter the total number of cells in a particular organ or tissue 
(Bertram, 2001). The abnormal proliferation of cells over many cell generations is clinically 
detectable as a neoplasm, which may be benign, pre-malignant, or malignant (Terpstra et 
al., 1987; Risio et al., 1993; Sandler et al., 2000). Genes that alter the production rate or 
death rate of individual cells have been implicated as causative in the carcinogenic process, 
with the origin of cancer being the accumulation of multiple random mutations within a cell 
(Loeb and Loeb, 2000; Campbell Marotta and Polyak, 2009). Very few mutations that give 
rise to cancer are inherited; most occur spontaneously due to DNA damage that results in 
the function of crucial genes being altered (Loeb and Loeb, 2000; Dove-Edwin and Thomas, 
2001; Matsuura et al., 2006). DNA damage may occur spontaneously either directly as a 
result of errors in replication, or indirectly due to damage to DNA caused by endogenous 
chemicals which leads to errors in the correct reading of the damaged DNA by DNA 
polymerase during replication (Jackson and Loeb, 2001). DNA may also be damaged by 
exogenous chemical and physical agents, which are known as environmental carcinogens 
(Multani et al., 2000). An example of a chemical carcinogen is 2-naphthylamine, used in 
rubber and chemical industries, which has been implicated as a bladder carcinogen 
(Bertram, 2001). Ionizing radiation and ultraviolet radiation are both examples of physical 
carcinogens (Ananthaswamy and Pierceall, 1990; Sachs and Brenner, 2005). Microbial 
carcinogens have also been implicated as a source of genetic change that gives rise to 
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cancer (van Poppel and van den Berg, 1997). Mutation rates and hence the rate of 
neoplastic progression are increased by defects in DNA repair mechanisms (Eshleman et al., 
1995; Ciotta et al., 1998). Several inherited diseases (for example the UV sensitivity disease 
xeroderma pigmentosum) which lead to cancer are caused by defects in DNA repair 
mechanisms (Bertram, 2001). 
 
Through the process of micro-evolution, cancer cells have acquired alterations in cell 
physiology that collectively result in malignant growth (Hanahan and Weinberg, 2011) 
(Figure 1.1). These alterations are as follows. Cancer cells are not under the control of 
external growth signals (both stimulatory and inhibitory) that regulate normal cell 
proliferation (Hornberg et al., 2006; Campbell Marotta and Polyak, 2009; Hanahan and 
Weinberg, 2011). They are able to evade apoptosis (i.e. programmed cell death) (Bertram, 
2001; Hornberg et al., 2006; Wicha et al., 2006; Campbell Marotta and Polyak, 2009; 
Hanahan and Weinberg, 2011). Cancer cells are able to avoid replicative senescence 
(through the reactivation of telomerase) and are therefore immortal and capable of infinite 
proliferation (Wicha et al., 2006; Hanahan and Weinberg, 2011). They have the potential to 
stimulate angiogenesis (the formation of new blood vessels and capillaries) thus ensuring an 
adequate supply of nutrients for growth and the elimination of metabolic waste products 
(Hornberg et al., 2006; Hanahan and Weinberg, 2011; Xu et al., 2011). They are genetically 
unstable (Bertram, 2001). Cancer cells are unable to communicate with neighbouring cells 
through gap junctions and are able to escape interactions with host cells (e.g. cells of the 
immune system) (Bertram, 2001). They are capable of metastasis, a multistep process that 
involves the dissociation of cancer cells from primary sites, survival in the vascular system, 
and proliferation in distant target organs (Hornberg et al., 2006; Wicha et al., 2006; 
Guadamillas et al., 2011; Hanahan and Weinberg, 2011; Kim et al., 2012). Cancer cells are 
therefore able to invade healthy tissues. Uncontrolled tumor growth and metastasis are the 
main origins of the pathological consequences of cancer, and both result from abnormal 
tumor cell proliferation, adhesion, invasion, and migration (Xu et al., 2011). 
 Figure 1.1: Acquired physiology of cancer cells.
An overview of the physiological traits acquired by c
malignant cell growth. (Adapted from 
 
1.2.3 Programmed cell death 
Apoptosis is an evolutionally conserved 
damaged or potentially harmful cells 
method of managing cancer, and many chemopreventive and/or chemotherapeutic agents 
can cause tumor cell death via the induction of apoptosis (Kim 
family of proteases that participate in apoptosis (Nelson and Cox,
initiated in two ways; by an extrinsic pathway, or by an intrinsic pathway (Hur 
Kim et al., 2010; Fauser et al
receptors are involved and the apoptosis signal is provided by the interaction between a 
death ligand (such as tumor necrosis factor (TNF)) 
activates the initiator caspas
Caspase-8 activates the effector caspase
apoptotic cell death (Hur et al
 
ancer cells, through micro-evolution
Hanahan and Weinberg, 2011). 
and carcinogenesis 
protective process that eliminates irreversibly 
from the body (Hur et al., 2008). 
et al., 2010). Caspases are a 
 2005). Apoptosis can be 
., 2011). In the extrinsic pathway, plasma membrane death 
and the death receptor, which then 
e-8 (Hur et al., 2008; Kim et al., 2010; Fauser 
-3 which cleaves several substrates, resulting in 
., 2008; Kim et al., 2010; Fauser et al., 2011
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, that lead to 
It is the preferred 
et al., 2008; 
et al., 2011). 
). The intrinsic 
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pathway is activated by stimuli from within the cell (e.g. DNA damage) which lead to a 
change in the permeability of the mitochondrial outer membrane, which in turn results in 
the release of cytochrome c into the cytosol (Hur et al., 2008; Kim et al., 2010). It is thought 
that the release of cytochrome c from the mitochondria into the cytosol is a key event in the 
intrinsic pathway (Kim et al., 2010). Once in the cytosol, cytochrome c binds to the Apaf-1 
complex thereby activating the effector, caspase-9, which in turn cleaves and activates 
caspase-3 (Hur et al., 2008; Kim et al., 2010; Fauser et al., 2011). Caspase-3 then cleaves 
several specific substrates, including poly (ADP-ribose) polymerase (PARP), which leads to 
apoptosis (Kim et al., 2010). Caspase activated cell death is regulated by genes including the 
pro- and anti-apoptosis genes, B-cell lymphoma 2 (Bcl-2) and Bcl-2-associated X protein 
(Bax), respectively, which induce apoptosis, either synergistically, or in opposition to one 
another (Fauser et al., 2011). 
 
Anoikis (or cell-detachment-induced apoptosis) is a form of caspase-mediated programmed 
cell death that results from a loss of contact with the extracellular matrix or neighbouring 
cells (Kim et al., 2012). It is a self-defence strategy that organisms use to eliminate 
‘misplaced’ cells, i.e. cells that are in an inappropriate location, and therefore prevent 
dysplastic growth (Guadamillas et al., 2011). Cancer cells use a variety of strategies to evade 
anoikis and thus escape the requirement for integrin-extracellular matrix interactions for 
cell proliferation (Guadamillas et al., 2011). The resulting anchorage-independent growth is 
a crucial step in the acquisition of malignancy (Guadamillas et al., 2011). Anoikis resistance 
and anchorage-independency allow tumor cells to expand and invade adjacent tissues, and 
to disseminate through the body, giving rise to metastases (Guadamillas et al., 2011; Kim et 
al., 2012).  
 
1.2.4 Carcinogenesis models 
There are two main types of carcinogenesis models, the stochastic model and the cancer 
stem cell model (Wicha et al., 2006). In the stochastic model, any cell can be the target of 
carcinogenesis, and the model proposes that transformation is caused by random mutation 
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followed by clonal selection (Wicha et al., 2006). The stem cell model proposes the 
existence of cancer stem cells which are defined as a subset of cancer cells that have the 
stem-cell-like ability to produce all cancer cell types present in a tumour, which may 
comprise cells with more differentiated features (Hamburger and Salmon, 1977; Campbell 
Marotta and Polyak, 2009). Cancer stem cells also serve as the seeds of metastatic spread of 
cancer (Hamburger and Salmon, 1977; Liu et al., 2011). They are likely to be derived from 
normal stem cells since these cells are present in almost all bodily tissues, are long-lived and 
therefore more likely than other cells to accumulate the multiple mutations required for 
carcinogenesis (Wicha et al., 2006; Campbell Marotta and Polyak, 2009). However, it has 
also been proposed that they may be derived from differentiated cells that have 
accumulated mutations and have de-differentiated back to the stem cell state (Campbell 
Marotta and Polyak, 2009). The extent to which cancer stem cells have normal stem cell 
properties is not clear (Campbell Marotta and Polyak, 2009). Previous studies indicate that 
most, if not all, malignancies are cancer stem cell driven and that these cells may be 
resistant to current therapeutic agents (Wicha et al., 2006). Cancer stem cells are thought to 
be involved in oncogenesis, tumor growth, metastasis, and cancer recurrence (Campbell 
Marotta and Polyak, 2009). 
 
1.2.5 Colon cancer and diet 
Colon cancer is one of the most frequent causes of cancer mortality in the world (Sack et al., 
2011). It is the third most common cancer worldwide and has the fourth highest mortality 
rate, accounting for 7.6% of cancer-related deaths (W.H.O., 2008). In South Africa, it is one 
of the leading cancers, accounting for 4.43% and 3.59% of new cases in 2004 in males and 
females respectively (The 2004 National Cancer Registry report). The reason for poor 
survival rates is because colon cancer is highly metastatic (Sack et al., 2011) and most cases 
are diagnosed at an advanced stage (Dove-Edwin and Thomas, 2001). Patients with 
nonmetastatic, local stage 1 tumors have a 5-year survival rate of 90% (Sack et al., 2011). 
However, this rate drastically drops to approximately 10% when distant metastases have 
formed at the time of diagnosis (Sack et al., 2011). 
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Evidence has been found to support the idea that dietary habits are a significant 
environmental factor in the overall cancer process (Bougnoux, 1999; Milner, 2004). Colon 
cancer occurs through the accumulation of multiple genetic mutations over a period of 
about 10-20 years in somatic cells; resulting in the progression of normal colonic mucosa to 
adenoma and finally to carcinoma (Dove-Edwin and Thomas, 2001). This process may be 
influenced by several lifestyle factors such as diet, exercise and other environmental factors 
(Dove-Edwin and Thomas, 2001; Matsuura et al., 2006). Most incidences of colorectal 
cancer have been found to be initiated by non-inherited, lifestyle factors (Dove-Edwin and 
Thomas, 2001; Matsuura et al., 2006). This suggests that colon cancer can be prevented to 
some degree by lifestyle alterations (Matsuura et al., 2006). Dietary prevention, 
chemoprevention and endoscopic intervention are current strategies employed in colorectal 
cancer prevention (Dove-Edwin and Thomas, 2001). Polyunsaturated fatty acids (PUFAs) 
have been implicated as important bioactive food components and a link between dietary 
intake of PUFAs and carcinogenesis has been proposed (Schloss et al., 1997; Bartsch et al., 
1999; Schley et al., 2005; Bougnoux et al., 2010; Lu et al., 2010). 
 
1.3 Polyunsaturated fatty acids 
1.3.1 Polyunsaturated fatty acids overview 
PUFAs are classified into two groups, omega-6 (n-6) and omega-3 (n-3) (Schmitz and Ecker, 
2008; Bougnoux et al., 2010). This classification is based on the position of the last double 
bond relative to the terminal methyl end of the molecule (Schmitz and Ecker, 2008). Both 
types of PUFA are termed essential since they are important for human health but cannot 
be synthesized de novo and must therefore be obtained through the diet (Bartsch et al., 
1999; Yao et al., 2006; Schmitz and Ecker, 2008; Arnold et al., 2010; Konkel and Schunck, 
2011). Since mammals (unlike plants, phytoplankton, or nematodes) lack the desaturases 
needed to introduce a double bond at the ω-6 or ω-3 position, they are unable to produce 
and interconvert n-6 and n-3 PUFAs (Konkel and Schunck, 2011). Linoleic acid (cis, cis-C18:2 
n-6) and α-linolenic acid (LNA, C18:3 n-3) are precursors in the n-6 and n-3 series 
respectively (Bougnoux et al., 2010). Linoleic acid is the predominant PUFA in the 
westernized human diet and is abundant in vegetable oils (such as those from soybeans, 
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corn and sunflowers) and food of animal origin (Bartsch et al., 1999; Schmitz and Ecker, 
2008; Bougnoux et al., 2010). LNA is found in dark green vegetables and in several vegetable 
oils, mainly linseed (50%), rapeseed (12%), soybean (7%), as well as in the fats of walnuts 
(6.8%) and other edible nuts (Bartsch et al., 1999; Crawford et al., 2000; Bougnoux et al., 
2010; Konkel and Schunck, 2011). In animals and humans, linoleic acid and LNA are 
metabolised to longer and more unsaturated n-6 and n-3 FAs respectively through 
desaturation and elongation pathways, with the desaturations being the rate limiting 
reactions (Crawford et al., 2000; Yao et al., 2006; Schmitz and Ecker, 2008) (Figure 1.2). 
Linoleic acid is converted to γ-linolenic acid (C18:3 n-6), and dihomo-γ-linolenic acid (C20:3 
n-6) to form the significant intermediate arachidonic acid (AA) (Schmitz and Ecker, 2008). AA 
is required as a constituent of membrane phospholipids (Konkel and Schunck, 2011). It may 
also be obtained directly from the diet through meat and dairy products (Konkel and 
Schunck, 2011) and is further metabolised to docosapentaenoic acid (C22:5 n-6) or 
eicosanoids by cyclo-oxygenase (COX), lipo-oxygenase (LOX) and cytochrome P450 (CYP) 
enzymes (Schmitz and Ecker, 2008; Arnold et al., 2010). The n-3 PUFA LNA is converted to 
stearidonic acid (C18:4 n-3) and eicosatetraenoic acid (C20:4 n-3), which is further 
metabolised to eicosapentaenoic acid (EPA) using the same series of enzymes used to 
synthesise AA (Schmitz and Ecker, 2008). EPA differs from AA solely by the presence of one 
additional double bond located between C17 and C18, and both EPA and AA are mainly 
incorporated into the sn-2 position of membrane phospholipids (Konkel and Schunck, 2011). 
EPA is further metabolised to docosahexaenoic acid (DHA) or eicosanoids (Schmitz and 
Ecker, 2008). DHA, the longest and most unsaturated n-3 PUFA, is the precursor of signalling 
molecules termed docosanoids, and is a crucial constituent of cell membranes particularly in 
the brain, retina and heart (Konkel and Schunck, 2011). It is important to note that the 
conversion of LNA to EPA and DHA is very limited in humans (Larsson et al., 2004; Konkel 
and Schunck, 2011). Furthermore, the desaturase and elongase genes controlling this 
metabolic pathway are highly polymorphic and are regulated by sex hormones, which leads 
to large interindividual differences in the efficiencies to convert LNA to EPA and DHA 
(Konkel and Schunck, 2011). Since n-3 and n-6 PUFA metabolism involves the same 
enzymatic system, competition exists between these FAs such that an excess of one causes 
a significant decrease in the conversion of the other (Crawford et al., 2000; Schmitz and 
Ecker, 2008; Konkel and Schunck, 2011). For these reasons, EPA and DHA need to be 
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obtained through the diet in order to meet the body’s requirements for these PUFAs 
(Konkel and Schunck, 2011). Deep cold-water fatty fish (e.g., mackerel, salmon and herring), 
fish oil and other sea food are a rich source of EPA and DHA since the marine food chain 
begins with EPA and DHA producing phytoplankton (Bartsch et al., 1999; Konkel and 
Schunck, 2011).  
 
 
Figure 1.2: Omega-6 and omega-3 polyunsaturated fatty acid metabolism. 
Compounds formed from n-3 and n-6 PUFA metabolism indicating general biological effects and enzymes 
involved. (Adapted from Schmitz and Ecker 2008; Gleissman et al., 2010). 
 
The ratio of n-6:n-3 PUFAs in the diet has been shown to be an important factor, however 
an optimal ratio has not been conclusively established (Bartsch et al., 1999; Rose and 
Connolly, 1999; Arnold et al., 2010). The ratio seems to be increasing over time, while the 
diet of Mesolithic man had a ratio of 1-4:1, European and Western diets now contain a ratio 
of 10-15:1 (Bartsch et al., 1999; Arnold et al., 2010). One of the highest ratios in the world is 
in Israel, 22-26:1 (Bartsch et al., 1999). A diet high in n-6 PUFAs was at one stage extensively 
recommended, however, it has recently been demonstrated that an excess intake of n-6 
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PUFAs may have long-term side-effects, including tumourigenesis, cardiovascular disease, 
hyperinsulinaemia and atherosclerosis (Bartsch et al., 1999; Arnold et al., 2010).  
 
FAs are incorporated into membrane phospholipids and thereby play an important role in 
membrane structure and function (Obermeier et al., 1995; Yao et al., 2006; Martins De Lima 
et al., 2007; Schmitz and Ecker, 2008). They strongly influence the fluidity of biological 
membranes, with an increase in unsaturated FAs resulting in an increase in membrane 
fluidity since PUFA acyl chains are flexible and can rapidly change conformational states 
(Schmitz and Ecker, 2008). By modulating membrane fluidity, FAs modify signal transduction 
across the cell membrane and thereby indirectly modulate intracellular signalling pathways 
(Obermeier et al., 1995; Martins De Lima et al., 2007). They can also act directly on cell 
membrane receptors (such as toll-like receptors, TLRs) or nuclear receptors (such as 
peroxisome-proliferator-activated receptors, PPARs) (Martins De Lima et al., 2007). Since 
the flexibility of acyl chains also differs significantly between n-3 and n-6 PUFAs, and the 
number of double bonds alters membrane fluidity, the n-3 and n-6 PUFAs composition of 
biological membranes significantly influences their physical properties, thereby altering 
protein function and trafficking, and vesicle budding and fusion (Schmitz and Ecker, 2008). 
FAs are also able to regulate key immune responses through the generation of biologically 
active metabolites (Martins De Lima et al., 2007). In general, the cellular free PUFA levels in 
normal tissues are low and almost undetectable (Yao et al., 2006). During inflammation, 
PUFAs are released from the membrane by phospholipase A2 and are oxidised by COX, LOX, 
and CYP enzymes to form physiologically important eicosanoid families, such as 
prostaglandins, thromboxanes, and leukotrines (Yao et al., 2006; Schmitz and Ecker, 2008) 
(Figure 1.2). In general, metabolites formed from AA are pro-inflammatory and thrombotic 
whilst those formed from EPA and DHA are anti-inflammatory, anti-thrombotic and pro-
resolving (Schmitz and Ecker, 2008; Gleissman et al., 2010).  
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1.3.2 Polyunsaturated fatty acids and cancer 
Epidemiological studies have revealed a link between high per capita fish consumption and 
lower incidence of cancer in the population. Eskimos, whose diet consists of fish and meat 
from marine mammals rich in n-3 FAs, and Japanese fishermen, who have the highest per 
capita fish consumption in the world, have high blood levels of long chain n-3 PUFAs, such 
as EPA, and low rates of cancers of the breast and colon, despite their overall high fat 
consumption (Bartsch et al., 1999). In South Africa, the incidence of colorectal cancer in the 
Cape Town urban population was 6.8 times greater than in the West Coast fisherman 
population during a study conducted over a period of 5 years (Schloss et al., 1997). This 
lower incidence of colorectal cancer in the fishermen was associated with a higher intake of 
fish by the fishermen (110 versus 30 g/day, P < 0.001). The study revealed that the daily 
intake of n-3 PUFAs, DHA and EPA, in the West Coast population was considerably higher 
than in the urban population due to their higher fish intake (Schloss et al., 1997). This led to 
higher levels of circulating DHA and EPA and lower levels of n-6 PUFAs in the fishermen’s 
plasma in comparison to the urban group (Schloss et al., 1997).  A study conducted by Lands 
et al. (1990) showed that an increase in saturated FA intake in the Japanese diet from 1960 
to 1985, together with a decrease in PUFA intake and a decrease in the n-3 to n-6 FA ratio 
has been linked to an increased incidence of colon and breast cancer in this society. 
 
In vitro and in vivo studies support the findings of epidemiological studies and have shown a 
correlation between PUFAs and cancer. Most studies have demonstrated that n-6 PUFAs, 
particularly AA, promote cancer (Schley et al., 2005; Ligo et al., 1997) or have no impact on 
cancer cell growth (Lu et al., 2010) whilst n-3 PUFAs, in particular EPA and DHA, have 
inhibitory effects on carcinogenesis (Ligo et al., 1997; Chamras et al., 2002; Schley et al., 
2005; Bougnoux et al., 2010; Lu et al., 2010). n-3 PUFAs, such as DHA or EPA, have also been 
found to improve cytotoxic effects of several anti-cancer drugs such as doxorubicin and 
paclitaxel, toward various human cancer cell lines, including those of breast, colon, bladder, 
neuroblastoma, and glioblastoma (Bougnoux et al., 2010). Dietary supplementation with 
DHA (0.7 g/day) has been found to increase the sensitivity of resistant tumors to chemo- 
and radiation therapy in animal models of breast cancer, with no additional toxicity to non-
12 
 
tumor tissues (Bougnoux et al., 2010). The addition of antioxidants abolished this sensitizing 
effect in a dose-dependent manner, suggesting that peroxidation of DHA is an important 
factor in this response (Bougnoux et al., 2010).  
 
The metastasis, to the lung, of the highly metastatic colon carcinoma Co 26Lu implanted 
subcutaneously on the right thighs of mice, or injected into the tail vein, was significantly 
reduced by EPA and DHA when administered at 0.2 ml per day (98% purity) (Ligo et al., 
1997). EPA and DHA were also found to result in a significant decrease in tumor growth of 
subcutaneous implanted Co 26Lu (Ligo et al., 1997). An in vitro study found EPA and DHA to 
be cytotoxic to Co 26Lu cells, having IC50 values of approximately 50 μM (Ligo et al., 1997). It 
was also found that the n-6 PUFA LA promoted Co 26Lu metastasis to the lungs when 
administered at 0.2 ml per mouse per day (98% purity) (Ligo et al., 1997). 
 
A study performed on Sprague-Dawley rats that were fed high fat diets (45% of total calories 
from fat) showed that a high intake of corn oil, a rich source of LA, stimulated colon cell 
proliferation (used as an intermediate biomarker for colon carcinogenesis); whilst a high 
intake of fish oil, a rich source of EPA and DHA, had a protective affect on colon cell 
proliferation (Kim et al., 1998). 
 
The molecular mechanism by which PUFAs affect carcinogenesis is not fully understood and 
several mechanisms have been proposed. One proposed mechanism is that n-3 PUFAs alter 
estrogen metabolism and therefore cause a reduction in estrogen-stimulated cell growth 
(Larsson et al., 2004). Approximately two thirds of breast cancers in women are hormone-
dependent and require estrogen for growth (Lu et al., 2010), and some other cancers, such 
as prostate cancer, have been found to be hormone-dependant (Huggins 1963; Etsuro, 
2000). Estrogen receptor α (ERα) and ERβ, members of the steroid/nuclear hormone 
receptor superfamily, are the two main estrogen receptors that mediate the actions of 
estrogen (Lu et al., 2010). ERα promotes estrogen-stimulated breast cancer cell 
proliferation, whilst ERβ inhibits it (Lu et al., 2010).  Lu et al. (2010) found that 
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supplementation with 10 and 60 μM DHA inhibits MCF-7 cell proliferation by proteasome-
dependent degradation of ERα and reduced cyclin D1 expression and mitogen-activated 
protein kinase (MAPK) signalling. EPA has also been implicated in this mechanism. 
Prostaglandin-2 is derived from AA and has been shown to stimulate the activity of 
aromatase P450, which converts 19-carbon steroids to estrogen (Larsson et al., 2004). In 
contrast, prostaglandin-3, which is derived from EPA, does not activate aromatase P450 
(Larsson et al., 2004). Therefore, a decrease in estrogen production and reduced estrogen-
stimulated cell growth is associated with an increased intake of EPA (Larsson et al., 2004).  
 
Another mechanism proposes that n-3 PUFAs influence transcription factor activity, gene 
expression, and signal transduction, leading to changes in metabolism, cell growth, 
differentiation, apoptosis, angiogenesis, and metastasis (Larsson et al., 2004). Schley et al. 
(2005) proposed that the decreased MDA-MB-231 cell proliferation and increased apoptosis 
observed during their study with EPA and DHA was caused by altered signalling through the 
Akt/NFκB (nuclear factor-kappaB) cell survival signalling pathway. Akt is a serine/threonine 
kinase that is activated in response to cytokines and growth factors (Schley et al., 2005). It is 
activated by translocation to the plasma membrane and phosphorylation at two key 
residues, namely Thr308 and Ser437 (Schley et al., 2005). Akt promotes cell survival and 
protects cells from apoptotic cell death by phosphorylating and inactivating components of 
the cell death machinery (Schley et al., 2005). Akt can also promote cell survival indirectly by 
activating prosurvival transcription factors such as NFκB (Schley et al., 2005). NFκB is a pro-
inflammatory transcription factor (Arnold et al., 2010). It protects cells from apoptosis and 
promotes cell growth by inducing the transcription of prosurvival and anti-apoptotic genes 
(Schley et al., 2005). Both Akt and NFκB have been found to be active in many human 
cancers (Schley et al., 2005). During their study, Schley et al. (2005) found that EPA and DHA 
decreased the phosphorylation of Akt (at Ser473) and significantly decreased the DNA 
binding activity of NFκB. 
 
The suppression of the biosynthesis of AA-derived eicosanoids has also been proposed as a 
mechanism by which n-3 PUFAs exert their anti-cancer activity (Larsson et al., 2004). 
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Inflammation has recently been shown to play a pivotal role in cancer (Serhan et al., 2004). 
Effectors and mediators of inflammation such as cytokines, chemokines, and eicosanoids 
form significant components of the tumor microenvironment (Gleissman et al., 2010). They 
have been found to support the growth and survival of malignant cells, promote 
angiogenesis and metastasis, affect adaptive immune responses, and alter the effect of 
hormones and chemotherapeutic drugs (Gleissman et al., 2010). EPA and DHA metabolites, 
eicosanoids and docosanoids, have potent anti-inflammatory and pro-resolution properties 
(Arnold et al., 2010; Gleissman et al., 2010).  They are therefore able to dampen the stimuli 
of these effectors and mediators, making the microenvironment less suited to tumor 
growth, which may lead to decreased cancer cell proliferation, metastasis, and 
angiogenesis; and increased apoptosis (Gleissman et al., 2010). A diet high in n-3 PUFAs 
reduces the production of AA-derived eicosanoids through several means. Firstly, since n-3 
PUFAs compete with n-6 PUFAs for desaturases and elongases, and n-3 PUFAs have greater 
affinities for the enzymes than n-6 PUFAs, a higher intake of n-3 PUFAs reduces the 
conversion of LA to AA and thus the production of AA-derived eicosanoids is decreased 
(Larsson et al., 2004; Arnold et al., 2010). Secondly, n-3 PUFAs suppress COX-2 and compete 
with AA for COX and LOX enzymes, thereby modulating the production and bioactivity of 
prostanoids and leukotrienes (Larsson et al., 2004; Arnold et al., 2010). Consequently, a 
higher intake of n-3 PUFAs results in a decrease in n-6 eicosanoid production (Larsson et al., 
2004). For example, AA is metabolised to leukotriene B4 (LTB4) by the enzyme 5-LOX (Arnold 
et al., 2010). LTB4 is a powerful inducer of inflammation and acts as a chemoattractant of 
neutrophils (Arnold et al., 2010). In the presence of EPA, LTB4 production is inhibited and 
LTB5 (a metabolite approximately 30 times less potent than LTB4) is metabolised from EPA 
(Arnold et al., 2010). Lastly, n-6 eicosanoid catabolism is enhanced by n-3 PUFAs through 
the induction of peroxisomal enzymes (Larsson et al., 2004). It is important to note that the 
potency of dietary EPA and DHA is approximately five times that of LNA for the suppression 
of AA-derived eicosanoids (Larsson et al., 2004). Gleissman et al. (2010) showed that 
neuroblastoma cells do not produce n-3 eicosanoids or docosanoids in the presence of EPA 
and DHA, despite the presence of the enzymes required for this conversion. This may be a 
survival strategy adopted by these cells (Gleissman et al., 2010). 
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Other proposed mechanisms for the effect on n-3 PUFAs on carcinogenesis include an 
increase in PUFA-derived reactive lipid compounds; an increase or decrease in the 
production of free radicals and reactive oxygen species (ROS); and mechanisms involving 
insulin sensitivity and membrane fluidity (Field and Schley, 2004; Larsson et al., 2004). 
PUFAs are the main intracellular substrates for lipid peroxidation; therefore PUFA-derived 
reactive lipid compounds could lead to necrosis through the damage of cell membranes 
(Field and Schley, 2004). The mechanism involving a decrease in free radicals and ROS has 
been linked to inflammation. It has been hypothesised that inflammation increases the 
production of free radicals and ROS, which leads to carcinogenesis (Larsson et al., 2004). 
ROS have been implicated as key second messengers during growth factor and cytokine 
stimulation to elicit prosurvival signals (Kim et al., 2012). n-6 PUFAs enhance these events 
through the production of AA-derived proinflammatory eicosanoids, whilst n-3 PUFAs 
suppress inflammation and thus the overproduction of free radicals and ROS, thereby 
suppressing carcinogenesis (Larsson et al., 2004). On the other hand, Gleissman et al. (2010) 
found that DHA induces cytotoxicity of neuroblastoma cells through the accumulation of 
ROS and mitochondrial-dependent apoptosis. In order to better understand the effects of 
PUFAs on carcinogenesis and the molecular mechanism by which they exert these effects it 
is important to have an understanding of how PUFAs are broken down in the body. 
 
1.4 Metabolism 
1.4.1 Cytochrome P450-mediated metabolism 
The CYP family of enzymes is one of the major drug metabolising systems in man (Glue and 
Clement, 1999). These enzymes are involved in the metabolism of various exogenous 
compounds including drugs, environmental chemicals and pollutants, and natural plant 
products (Nebert and Russell, 2002). This enzyme system has also been shown to 
metabolise many endogenous substrates including saturated and unsaturated fatty acids, 
eicosanoids, sterols and steroids, prostaglandins, bile acids, vitamin D and retinoids (Nelson 
et al., 1993; Liska 1998; Adas et al., 1999; Yao et al., 2006). Although it was originally 
believed that these enzymes were predominantly present in the liver, they have been 
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shown to be expressed in almost all cell types in mammals; being found in the endoplasmic 
reticulum and mitochondria (Glue and Clement, 1999; Nebert and Dieter, 2000; Chen et al., 
2001). CYP proteins are arranged into families and subfamilies according to amino acid 
sequence identity. Enzymes that share ≥ 40% identity are allocated to a particular family 
designated by an Arabic numeral, and those sharing ≥ 55% identity form part of a subfamily 
within that family, designated by a letter (Nelson et al., 1993). There is a highly conserved 
amino acid sequence found in some bacteria and nearly all eukaryotic cells (Glue and 
Clement, 1999). It is a 26-residue region found near the carboxy terminus of CYP proteins, 
the heme-binding domain (Glue and Clement, 1999). There are more than 270 different CYP 
gene families currently identified, with CYP2 being the largest P450 family in mammals 
(Nebert and Russell, 2002). In humans, there are 57 CYP genes and 33 pseudogenes 
arranged into 18 families and 42 subfamilies (Nebert and Russell, 2002). 
 
Metabolism can be broken down into two groups, namely Phase 1 reactions and Phase 2 
reactions (Glue and Clement, 1999). Phase 1 reactions involve the chemical alteration of a 
compounds structure (e.g., by oxidation), whilst Phase 2 reactions are conjugation reactions 
(e.g., glucuronidation) (Glue and Clement, 1999). CYP enzymes are the main enzymes 
involved in Phase I metabolism (Pearce et al., 1996; Yamazaki and Shimada, 1997; Liska, 
1998; Yao et al., 2006). They are a superfamily of heme-containing monooxygenases (Adas 
et al., 1999; Domanski and Halpert, 2001) and represent the most abundant and extensively 
distributed group of eukaryotic monooxygenases (Chen et al., 2001). CYPs catalyze both 
oxidative and reductive reactions, with oxidative biotransformations being more frequent 
(Guengerich, 2001; Cruciani et al., 2005). These oxidative reactions include side chain and 
aromatic hydroxylation, N-, O-, S-dealkylation, N-oxidation, sulfoxidation, N-hydroxylation, 
deamination, dehalogenation, and desulfuration (Glue and Clement, 1999; Cruciani et al., 
2005). Most of these reactions involve the formation of radical species, which is normally 
the rate-limiting step (Cruciani et al., 2005). CYPs contain a protoporphyrin group with a 
central iron atom that is hexacoordinated in ferric form (Cruciani et al., 2005). The substrate 
binds reversibly to the enzyme, and the complex undergoes reduction to the ferrous state 
(Cruciani et al., 2005) (Figure 1.3). The electrons come from a reduced cofactor (NADH or 
NADPH) (Glue and Clement, 1999; Guengerich, 2001). This cofactor passes electrons to the 
 CYPs heme prosthetic group through the intermediary enzyme cytochrome P450 reductase 
(Chapple, 1998). The reduction of the iron atom to the ferrous state
oxygen to bind the enzyme-substrate complex
oxygen is converted to oxene, an electrophilic and reactive species, which 
hydrogen radical away from the substrate and transfers a hydroxyl group back
1998; Cruciani et al., 2005; Gonzalez and Tukey, 2005
and is ready for a new cycle (Cruciani 
consuming more O2 than substrate metabolised and therefore resulting in the formation of 
O2
-
 which is usually converted to water by the enzyme superoxide dismutase (
Tukey, 2005). Phase I detoxification 
carboxylation of relatively insoluble (lipophilic) organic compounds, causing them to 
become more polar water-soluble 
down further (through conjugation in Phase 2 metabolism) 
(Lewis et al., 1998; Glue and Clement, 1999
Figure 1.3: Cytochrome P450 catalytic cycle.
Fe = iron atom in CYP heme prosthetic group, RH = substrate, ROH = product, red and ox indicate the reduced 
and oxidised states of the intermediary 
transferred from NADPH to CYPs heme 
second electron is transferred 5) Cleavage of the oxygen bond. 6) Release of water and for
intermediate. 7) Removal of hydrogen from substrate to form radical. 8) Radical captures hydroxyl from heme 
iron to form product. 9) Product released and CYP ready for another catalytic cycle. 
Guengerich, 2001). 
 (Guengerich, 2001; Cruciani 
). The CYP then releases the product 
et al., 2005). For most CYPs, the reaction is uncoupled, 
therefore involves the CYP-dependent hydroxylation
compounds and thereby allowing them to be broken 
and/or excreted 
). 
 
enzyme CYP reductase 1) Substrate binds. 2) A single electron is 
group through CYP reductase. 3) Oxygen is now able to bind. 4) A 
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et al., 2005). The 
typically draws a 
 (Chapple, 
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from the body 
 
mation of ferryl 
(Adapted from 
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During Phase II metabolism, enzymes (such as uridine diphosphate-
glucuronosyltransferases, glutathione transferases, and sulfotransferases) conjugate the 
newly generated hydroxyl or carboxyl groups to polar substances such as glucuronic acid, 
glycine, sulphate, and acetate, which further increases the substrates aqueous solubility 
(Lewis et al., 1998; Liska, 1998; Nebert and Dieter, 2000). Phase II reactions therefore 
involve cofactors which have to be replenished through dietary sources (Liska, 1998). The 
combined result of Phase I and Phase II detoxification is the biotransformation of a lipophilic 
compound to a water-soluble compound that is able to be excreted through urine or bile 
(Liska 1998). Although CYP enzymes most likely evolved to detoxify and help eliminate 
harmful substances, in some cases they have been shown to convert relatively harmless 
compounds to toxic metabolites that contribute to increased risks of cancer initiation, 
promotion, and progression; birth defects; and other toxic effects (Nelson et al., 1993; 
Nebert and Russell, 2002; Guengerich, 2006). For example, environmental carcinogens have 
great chemical stability, but form highly reactive chemical species through a process of 
metabolic activation by the enzymes involved in the detoxification of xenobiotic compounds 
(Bertram, 2001). Having an understanding of CYP metabolism is important since it provides 
a basis for the explanation and prediction of certain compound interactions; offers 
guidelines for dose selection (or appropriate dietary concentrations in the case of PUFAs) in 
some patient groups; and may explain unexpected toxicity or lack of efficacy (Glue and 
Clement, 1999). 
 
1.4.2 Cytochrome P450-mediated metabolism of polyunsaturated fatty acids 
CYP-mediated metabolism of PUFAs generates hydroxy-fatty acids, di-hydroxy-fatty acids, 
and epoxy-fatty acids (Larsson et al., 2004; Fer et al., 2008a) (Figure 1.4). In terms of EPA, 
DHA, and AA; EPA is the preferred substrate for the majority of CYP isoforms, with DHA and 
AA having similar metabolism rates (Arnold et al., 2010). The CYP4 family, containing 5 
subfamilies and 12 members, has been implicated in FA metabolism (Nebert and Russell, 
2002). The CYP4A subfamily is a group of conserved, specialized FA hydroxylases that have 
been found to have little activity toward the majority of other characteristic CYP substrates 
(Domanski and Halpert, 2001). Konkel and Schunck (2011) showed that liver and renal 
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microsomal CYP enzymes metabolise EPA and DHA by epoxidation and hydroxylation. The n-
3 double bond that distinguishes EPA and DHA from their n-6 counterparts is a predominant 
site of epoxidation for many CYP isoforms, including several members of the CYP4A 
subfamily (Arnold et al., 2010; Konkel and Shunck, 2011). The main EPA metabolites 
produced by CYPs include ω/(ω-1)-hydroxyeicosapentaenoic acids (20- and 19-HEPE) and 5 
regioisomeric epoxyeicosatetraenoic acids (EpETEs) (Arnold et al., 2010; Konkel and 
Schunck, 2011). DHA is metabolised by CYPs to ω/(ω-1)-hydroxydocosahexaenoic acids (22- 
and 21-HDoHE) and 6 regioisomeric epoxydocosapentaenoic acids (EpDPEs) (Arnold et al., 
2010; Konkel and Schunck, 2011). Fer et al. (2008b) tested a range of human recombinant 
CYPs and found that CYP2C9/2C19 and 1A2 were the most efficient epoxygenases of EPA 
and DHA. They also found that in human liver microsomes, the hydroxylase activity was 
greater than the epoxygenase activity (Fer et al., 2008b). Adas et al. (1999) showed that 
fatty acid (ω-1)-hydroxylase activity is catalysed by CYP2E1 in the mammalian species, while 
the FA ω-hydroxylase activity may be catalysed by CYPs from the 4A family. Van Rollins et al. 
(1983) found that the main CYP metabolites of DHA produced in rat liver microsomes were 
19, 20-; 16, 17-; 13, 14-; 10, 11-; and 7, 8- dihydroxydocosapentanoic acids and 22- and 21-
hydroxydocosahexaenoic acids. These major products were a result of three classes of 
oxidation, namely, ω-hydroxylations, (ω-1)-hydroxylations and epoxidations (Van Rollins et 
al., 1983). 
 
Arachidonic acid is metabolised by CYP epoxygenases to four regioisomers termed cis-
epoxyeicosatrienoic acids (EETs) (Jiang et al., 2007; Xu et al., 2011), as well as other 
bioactive eicosanoids termed hydroxyeicosatetraenoic acids (HETEs) (Node et al., 1999). 
EETs are further metabolised to dihydroxyeicosatrienoic acids (DHETs) which are more 
stable and less biologically active than EETs (Xu et al., 2011). CYP4A and CYP4F are AA ω/(ω-
1)-hydroxylases, producing 20-hydroxyeicosatetraenoic acid (20-HETE) as their predominant 
product (Arnold et al., 2010). The CYP2 family of epoxygenases are the main enzymes 
involved in EET formation, with CYP2J2 being a predominant human AA epoxygenase that 
generates all four EETs, namely 5,6-; 8, 9-; 11,12-; and 14,15-EET, through the addition of an 
epoxide group to one of the four double bonds of AA  (Jiang et al., 2007; Xu et al., 2011). 
CYP2J2 is mainly expressed in endothelium cells and myocardiocytes (Xu et al., 2011). EETs 
 have been found to be antihypertensive and organ
of anti-inflammatory and anti
injury (Arnold et al., 2010).   
 
Figure 1.4: Cytochrome P450-dependent metabolism of AA, EPA and DHA.
Phospholipase A2, activated by various hormones and growth factors via G
releases AA, EPA and DHA from membrane phospholipids. The free FAs compete for conversion by CYPs, with 
EPA being the preferred substrate for many CYP isoforms. CYP 
epoxidation of the FAs. Nitric oxide (NO), carbon monoxide (CO) and reactive oxygen species (ROS), which are 
produced in variable amounts depending on inflammation and other
from Arnold et al., 2010). 
 
 
1.5 Rationale and motivation
The positive effects and dietary benefits of n
previously reported. On the other hand, m
have no impact on carcinogenesis. 
PUFAs influence carcinogenesis it is important to gain knowledge about their metabolism 
and comprehend how their effects wil
effects of AA, EPA and DHA CYP
reported or compared to the effects of the parent compounds. This information is 
-protective, implicated in the mediation 
-apoptotic mechanisms that protect against cell and organ 
 
-protein coupled receptors (GPCR), 
metabolism results in hydroxylation and 
 disease states, inhibit CYPs
 
-3 PUFAs on carcinogenesis have been 
ost studies report that n-6 PUFAs promote or 
In order to have a better understanding of how these 
l be altered upon transformation in the body. 
 metabolites on colon carcinoma have not 
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important since it would determine whether the parent compound or its metabolite is 
having a greater effect.  
 
1.6 Hypothesis 
We hypothesised that EPA, DHA and AA would be metabolised by CYP enzymes within a 
human liver microsomal system in vitro and that the effects of the parent and metabolite on 
colon cancer cell biology would differ.  
 
1.7 Objectives 
The objectives of this research project were as follows: 
 
1. Prediction of EPA, DHA and AA metabolites in silico. 
2. Detection and in vitro metabolism of EPA, DHA and AA. 
I. Analytical method development and validation. 
II. Optimisation of a human liver microsomal system for in vitro metabolism of 
EPA, DHA and AA.  
3. Assessment of the effect of EPA, DHA and AA on colon cancer cell viability. 
4. Comparison of the effects of the parent compounds and their CYP metabolites on 
colon cancer cell biology. 
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Chapter Two 
In Silico Metabolism of EPA, DHA and AA 
2.1 Introduction 
Determining the metabolic biotransformations a compound will undergo in the body is 
important since these transformations will directly affect the compounds bioavailability, 
activity, toxicity, distribution, and elimination from the body (Korolev et al., 2003). 
Determination of the site of metabolism is relevant because through the addition of stable 
groups or steric shields at the metabolically susceptible position, or the removal or 
replacement of metabolically susceptible groups, labile compounds can be stabilized 
(Cruciani et al., 2005).  One important implication of this is that the formation of toxic 
metabolites can be prevented (Cruciani et al., 2005). Knowledge of the site of metabolism is 
also significant in cases where metabolism results in the compound becoming active, and in 
compounds which exhibit excessively long half lives (Cruciani et al., 2005). Information 
about where functional groups are metabolised can lead to improved pharmacokinetics, for 
example increased bioavailability and half-life, through the blockage of the major site of 
metabolism for the compound (Cruciani et al., 2005). In silico studies which use 
computational predictive methods to identify potential sites of metabolism are useful tools 
in early metabolism studies. Since the kinetic profile of a compound is highly dependent on 
the compounds biotransformation by CYP enzymes during phase 1 metabolism, prediction 
of the sites of metabolism during these reactions is usually the starting point in many in 
silico analyses (Cruciani et al., 2005; Rydberg et al., 2010).  SMARTCyp and MetaSite are two 
predictive softwares that are available for such in silico predictions.  
 
SMARTCyp is a rule-based web application for CYP-mediated site of metabolism predictions. 
SMARTCyp is able to use the 2D structure of a molecule and doesn’t require the generation 
of 3D structures (Rydberg et al., 2010). The SMARTCyp algorithm involves two descriptors, 
namely a reactivity descriptor, E, and an accessibility descriptor, A (Rydberg et al., 2010). 
The reactivity descriptor is an estimation of the energy required for a CYP to react at a 
specific atom whilst the accessibility descriptor describes the position of the atom relative 
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to the 2D centre of the molecule (Rydberg et al., 2010). The score, S, for each atom is 
calculated according to the following equation: 
S = E – 8A 
with a lower score indicating a higher probability of being a site of metabolism (Rydberg et 
al., 2010). The constant 8 allows for slightly less reactive atoms, which have a significantly 
greater accessibility, to be ranked higher (Rydberg et al., 2010). Reactivity rules are based 
on reaction steps requiring the highest activation energy for the respective reactions 
(Rydberg et al., 2010). This reaction step is a hydrogen extraction from a carbon atom for 
hydroxylation and dealkylation reactions; and the attack of the oxygen on the respective 
atom for oxidation and epoxidation reactions (Rydberg et al., 2010). 
 
MetaSite is a fully automated software program that is able to predict the site of 
metabolism, isoform selectivity, and ligand-cytochrome complementarity during CYP-
mediated phase 1 metabolism in humans, and encompasses all the cytochromes for which 
3D structure is known (Cruciani et al., 2005). This software also provides information about 
the predicted metabolites monoisotopic mass, partition coefficient (log P) and distribution 
coefficient (log D) which are important factors in the evaluation of the drug-likeness of a 
compound using the Rule of 5 (Ro5) (Lipinski et al., 2001). The advantage that MetaSite has 
over rule-based methods is that it is human-specific and therefore produces a relatively 
smaller number of possible final metabolites with a greater amount of accuracy (Cruciani et 
al., 2005). The program requires the user to input the substrate’s structure in SMILES 
notation, 2D SDF format, or 3D coordinates. The computational method involves the 
calculation of two sets of descriptors, one for the CYP enzyme and one for the substrate of 
interest, which then represent the chemical fingerprint of the enzyme and the substrate 
respectively (Cruciani et al., 2005). The descriptors created for the enzyme are independent 
of the initial side chain position of the CYP 3D structure and are therefore able to simulate 
the adaptation of the enzyme to the substrate structure better (Cruciani et al., 2005). The 
fingerprint created for the potential substrate is composed of four descriptor sets, one set 
for each of the following atom categories: hydrophobic, hydrogen-bond acceptor, hydrogen-
bond donor and charged (Cruciani et al., 2005). The descriptors are used to compare the 
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cytochrome fingerprint with that of the substrate (Cruciani et al., 2005). The sites of 
metabolism are then ranked based on a calculation of the approximate free energy required 
for the reaction to occur (Cruciani et al., 2005). This is calculated using the following 
equation: 
Psm(i) = EiRi 
where Psm(i) represents the probability for the site of metabolism at atom i of the substrate. 
Ei represents a score proportional to the accessibility of atom i toward the reactive heme 
and is dependent on the 3D structure, conformation, and chirality of the substrate; and the 
3D structure and side chain flexibility of the CYP enzyme. Ri represents a score proportional 
to the reactivity of atom i in a specific reaction mechanism (representing the activation 
energy required to produce the reactive intermediate) and is dependent on the 3D structure 
of the substrate and on the reaction mechanism. Therefore, an atom i needs to possess 
significant accessibility and reactivity components related to the heme in order to be 
classified as a site of metabolism (Cruciani et al., 2005).   
 
In this chapter, MetaSite and SMARTCyp were used to predict the possible sites of 
metabolism for EPA, DHA and AA during the CYP-mediate reactions of phase 1 metabolism. 
MetaSite was also used to determine important Ro5 parameters. 
 
2.2 Methods and Materials 
SMARTCyp (www.farma.ku.dk/smartcyp) and MetaSite (Molecular Discovery Ltd., 
Middlesex, UK) were used for the in silico metabolism of EPA, DHA and AA. Both are fully 
automated computational procedures that predict and rank the possible sites of metabolism 
during the CYP-mediated reactions of phase-1 metabolism. MetaSite was also able to 
predict the possible metabolites that will be formed along with their monoisotopic masses, 
log P and log D values. The twelve most likely sites of metabolism as predicted by 
SMARTCyp and MetaSite are reported as well as the twelve most likely metabolites 
predicted by MetaSite along with their monoisotopic masses, log P and log D values. 
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2.3 Results 
The three most likely sites of metabolism predicted by MetaSite for EPA were formed 
through aliphatic hydroxylation and occurred at C13, C16 and C19 (Table 2.1 and 2.2). C16 
and C13 were also ranked in the top three sites of metabolism by SMARTCyp with C13 being 
ranked as the second site and having an equal probability with C7 (Table 2.1). These 
reactions were also predicted to be hydroxylation reactions by SMARTCyp. The n-3 double 
bond was ranked 8
th
 and 9
th
 by Metasite (olefinic epoxidation) and 5
th
 and 6
th
 by SMARTCyp 
(hydroxylation) (Table 2.1 and 2.2). The ω and ω-1 carbon atoms (C20 and C19) were ranked 
6
th
 and 3
rd
 by Metasite, and 19
th
 and 7
th
 by SMARTCyp, with both programs predicting these 
to be hydroxylation reactions.  
 
The three most likely sites of metabolism for DHA predicted by Metasite were C12 and C15 
(with equal probability) and C18, with aliphatic hydroxylation being the proposed 
mechanism (Table 2.1 and 2.2). Both C15 and C18 were ranked within the three most likely 
sites of metabolism by SMARTCyp, with the ranking order being C18, C6 and C15 
respectively and the predicted mechanism being hydroxylation (Table 2.1). The n-3 double 
bond was ranked 15
th
 and 16
th
 by Metasite (data not shown) and 6
th
 and 7
th
 by SMARTCyp 
(hydroxylation) (Table 2.1). The ω and ω-1 carbon atoms (C22 and C21) were ranked 9
th
 and 
4
th
 by Metasite, and 21
st
 and 8
th
 by SMARTCyp, with both programs predicting these to be 
hydroxylation reactions (Table 2.1 and 2.2).  
 
The three most likely sites of metabolism for AA according to Metasite were C19, C13 and 
C16, with the mechanism being that of aliphatic hydroxylation for C19 and C13, and 
dehydrogenation for C16 (Table 2.1 and 2.2). SMARTCyp predicted the three most likely 
sites of metabolism to be C7, C13 and C10, with the mechanism being hydroxylation (Table 
2.1). The ω and ω-1 carbon atoms (C20 and C19) were ranked 7
th
 and 1
st
 by MetaSite, and 
19
th
 and 15
th
 by SMARTCyp (Table 2.1 and 2.2). 
 
 Table 2.1: A comparison of the 
The twelve most likely sites of metabolism are indicated on the relative structures using the colour coding 
illustrated at the bottom of the table. The sites of metabolism are also listed in ra
carbon atoms having the same probability represented in colour. Carbon numbering from the carboxy 
terminal. 
rank of metabolism sites predicted by MetaS
nk order in parentheses, with 
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 Table 2.2: Metasite metabolite predictions for EPA, DHA and AA. 
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(302.22; 7.24; HE; 5.14; 3.96; OJ 
or 
~ 
(318.22; 5.79; 5.64; 3.69; 2.39; AC) 
(31.0 .l.4; 5.47; 5.32.; 3.37; 2..19; AH ) 
 Summary of the 12 most likely CYP-
MetaSite. Monoisotopic masses (MiM), 
in parentheses in that order. Note that log 
the numerical subscripts represent the respective pH.
Epoxidation OE; Dehydrogenation D; Aliphatic Carbonylation AC.
 
 
mediated phase 1 metabolites of EPA, DHA and AA as predicted by 
log P, log D4, log D7, log D9, and the proposed mechanism are indicated 
D is a pH dependent version of the partition coefficien
 Mechanism key: Aliphatic hydroxylation: AH; Olefinic 
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2.4 Discussion 
CYP-mediated metabolism of PUFAs has been found to generate hydroxy-, di-hydroxy-, and 
epoxy-fatty acids (Larsson et al., 2004; Fer et al., 2008a). MetaSite predictions encompassed 
all three of these metabolite types, but SMARTCyp was limited in its predictions because it 
was only able to predict that the transformation that would occur during CYP metabolism of 
FAs would be a hydroxylation. This is a restrictive factor for SMARTCyp since it simply 
predicts that all transformations that occur at a carbon atom will be hydroxylation reactions. 
Another limiting factor of SMARTCyp is that it is bias towards the CYP3A4 isoform. The 
SMARTCyp method identifies the sites in a molecule that are most reactive with regard to 
CYP-mediated reactions (Rydberg et al., 2010). Since the 3A4 isoform has the largest active 
site and the most flexible structure, it is the most promiscuous isoform, with small 
restrictions on the size and shape of its substrates (Rydberg et al., 2010). Reactivity is 
therefore key in determining the site of metabolism for this isoform, and since SMARTCyp is 
foremost a reactivity model, it shows a preference for predicting sites that are metabolised 
by the CYP3A4 isoform (Rydberg et al., 2010).  
 
The n-3 double bond of EPA and DHA has previously been found to be a major site of 
epoxidation for many CYP isoforms (Konkel and Shunck, 2011). It was therefore expected 
that this site would be ranked as a likely site of metabolism by Metasite and SMARTCyp, and 
that the predicted mechanism would be that of epoxidation. For both EPA and DHA, 
Metasite predicted that the transformation that would occur at this double bond would be 
an olefinic epoxidation. For EPA, this site was ranked 8
th
 through to 12
th
 and for DHA it was 
ranked 15
th
 and 16
th
. SMARTCyp ranked this double bond 5
th
 and 6
th
 for EPA and 6
th
 and 7
th
 
for DHA, however the predicted mechanism was not that of epoxidation, but rather 
hydroxylation due to SMARTCyp’s limitations.  
 
Previous studies have found that AA is metabolised by CYP epoxygenases to four 
regioisomers termed cis-epoxyeicosatrienoic acids (EET) (Jiang et al., 2007). These 
metabolites were however not predicted by MetaSite or SMARTCyp. AA has also been found 
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to be metabolised to dihydroxyeicosatrienoic acids (DHETs) and hydroxyeicosatetraenoic 
acids (HETEs) (Node et al., 1999). MetaSite and SMARTCyp did not predict the formation of 
DHETs but were able to predict the formation of HETEs.  
 
It was expected that the ω/(ω-1) position would be ranked as a likely site of hydroxylation 
for EPA, DHA and AA (Konkel and Schunck, 2011). Both programs predicted the 
transformation that would occur at these carbon atoms to be hydroxylation reactions. For 
EPA, the ω carbon was ranked 6
th
 and 19
th
 and the ω-1 carbon 3
rd
 and 7
th
; for DHA, the ω 
carbon was ranked 9
th
 and 21
st
 and the ω-1 carbon 4
th
 and 8
th
; for AA, the ω carbon was 
ranked 7
th
 and 19
th
 and the ω-1 carbon 1
st
 and 15
th
 by MetaSite and SMARTCyp respectively. 
Both programs therefore predicted the ω-1 carbon to be a greater site of metabolism than 
the ω carbon. SMARTCyp ranked the ω carbon as the second to last possible site of 
metabolism for all three FAs. 
 
The Rule of 5 (Ro5) is used to evaluate drug-likeness of compounds, i.e. it gives an indication 
of whether a chemical compound has pharmacokinetic properties that would make it a 
suitable orally administered therapeutic agent (Bhal et al., 2007). The Ro5 states that in 
order for a compound to be considered drug-like it must have a molecular weight less than 
500; a partition coefficient (log P) less than 5; less than 5 hydrogen bond donor atoms; and 
less than 10 nitrogen and oxygen atoms combined (Lipinski et al., 2001; Bhal et al., 2007). 
Compounds that violate these rules show poor pharmacokinetic properties for oral 
administration (Bhal et al., 2007). Log P (the partition coefficient) is a measure of 
lipophilicity that describes the differential partitioning of a neutral compound between two 
immiscible solvents, most commonly octan-1-ol and water (Bhal et al., 2007). The MetaSite 
predicted metabolites of EPA, DHA and AA all have log P values greater than 5. When 
considering log P values only, these compounds will be strongly lipophilic, which is expected 
since they are derived from fatty acids. The problem with highly lipophilic compounds is that 
they are likely to be rapidly metabolised and bioaccumulated, have low aqueous solubility 
and poor absorption properties (Bhal et al., 2007). However, log D values also need to be 
taken into account, which need to be equal to or less than 5 in order for the compound to 
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pass lipophilicity screening (Bhal et al., 2007). Log D is a pH dependent version of log P and it 
describes the octanol-water distribution coefficient for partitioning of ionisable species in 
biphasic media (Bhal et al., 2007). Log D is important since the pH of the body varies 
between different organs and so the ionic state of the compound of interest will vary 
depending on the pH of the immediate physiological conditions (Bhal et al., 2007).  The log 
D4 values are above five for the EPA, DHA and AA metabolites, except for the predicted 
metabolites 3, 7, 8 and 9 for EPA, and 8, 9 and 12 for DHA (Table 2.2). The log D7 and D9 
values are below 5 for all the EPA, DHA and AA predicted metabolites (except metabolite 4 
for AA). All MetaSite predicted metabolites for EPA, DHA and AA have molecular weights 
less than 500; less than 5 hydrogen bond donor atoms; and less than 10 nitrogen and 
oxygen atoms combined. This in combination with the fact that they have log D7 and D9 
values less than 5 means that these metabolites have pharmacokinetic properties that 
would make them suitable for oral administration.  
 
2.5 Conclusion 
In silico studies are a good starting point during the determination of a compounds CYP-
mediated phase 1 metabolism. However, these findings should be checked against literature 
and validated via in vitro studies. When performing in silico analyses, it is important to have 
a basic understanding of the mechanism by which the chosen software will perform its 
predictions. It is also important to have an understanding of the limitations of the chosen 
program. For the determination of FA metabolites in silico, MetaSite is a more efficient tool 
than SMARTCyp. This is because MetaSite is able to not only predict and rank the possible 
sites of metabolism, but it is also able to give information about the reaction type as well as 
monoisotopic masses and log P and log D values. Other advantages of MetaSite are that it is 
human specific and that it is not rule based, but rather, relies on the 3D structure of the 
different CYP isoforms (Cruciani et al., 2005). Since SMARTCyp is a rule- and 2D-based 
method, it has the disadvantage that highly reactive sites, which are not accessible in 3D 
space, are still ranked quite high (Rydberg et al., 2010). Another disadvantage of SMARTCyp 
is that it is bias toward the 3A4 isoform. The SMARTCyp reactivity parameter can be 
complemented with additional descriptors and empirical knowledge to increase accuracy 
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and create models for other CYP isoforms (Rydberg et al., 2010), but this process is 
complicated. However, if SMARTCyp is the chosen method for in silico metabolism, it would 
be far more accurate if the program was adapted to incorporate CYP isoforms known to 
metabolise the compound of interest. 
 
In conclusion, both MetaSite and SMARTCyp predicted that EPA, DHA and AA will be 
metabolised by CYP enzymes through hydroxylation. MetaSite was also able to predict the 
formation of di-hydroxy- and epoxy-FAs. All MetaSite predicted metabolites for EPA, DHA 
and AA showed suitable pharmacokinetics for oral administration since they satisfied the 
criteria of the Ro5. 
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Chapter Three 
In Vitro Metabolism of EPA, DHA and AA 
3.1 Introduction 
In vitro studies are useful for determining: the metabolism of compounds that do not have 
toxicological profiles; mechanisms of metabolism in more detail; potential compound-
compound interactions; effects of environmental agents, ethnic background, gender, and 
genetics on the compounds’ metabolism; and for biologically generating reference 
standards when chemically synthesized metabolite standards are not available (Wrighton et 
al., 1995; Scarth et al., 2010). Studies have shown that in vitro metabolism assays are as 
effective as in vivo assays and result in the same metabolite profile (Scarth et al., 2010). In 
vitro methods for the study of human liver drug metabolism can be divided into two 
categories, namely cellular models and drug-metabolising enzyme preparations (Wrighton 
et al., 1995). Cellular models include primary hepatocytes, liver slices, and hepatocyte 
derived cell lines; drug-metabolizing enzyme preparations include tissue homogenates, 
subcellular fractions (such as microsomal and cytosolic fractions), and isolated enzymes 
(Wrighton et al., 1995). The most commonly used system for in vitro metabolism studies has 
been the use of subcellular fractions (Wrighton et al., 1995).  
 
Metabolism of many exogenous compounds (such as drugs) as well as many endogenous 
compounds (such as fatty acids) occurs in two stages, namely phase 1 and phase 2 (Glue and 
Clement, 1999). Phase 1 reactions encompass oxidation, reduction, and hydrolytic reactions, 
and lead to the conjugation of -OH, -COOH, -SH, -O- or NH2 functional groups to the 
compound (Glue and Clement, 1999; Cruciani et al., 2005; Gonzalez and Tukey, 2005). These 
functional groups often dramatically alter the biological properties of the metabolite and 
may lead to either the inactivation of an active compound or, in some cases, the 
bioactivation of compounds (Gonzalez and Tukey, 2005). Phase 2 reactions involve the 
covalent conjugation of hydrophilic moieties (such as glutathione, glucuronic acid and 
sulphate) to the products formed during phase 1 (Lewis et al., 1998; Liska, 1998; Gonzalez 
and Tukey, 2005). The attachment sites for these hydrophilic moieties are usually the 
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oxygen, nitrogen and sulphur atoms added during phase 1 metabolism (Gonzalez and Tukey, 
2005). The result of phase 2 metabolism is a compound with increased molecular weight 
and polarity, thus facilitating its elimination from the body (Gonzalez and Tukey, 2005).  
 
CYPs are a family of heme-containing monooxygenases responsible for the majority of phase 
1 metabolism (Yao et al., 2006). These enzymes are located in the endoplasmic reticulum 
within the living eukaryotic cell (Gonzalez and Tukey, 2005). When eukaryotic cells are 
broken up, closed vesicle-like structures containing CYP enzymes are formed from the 
endoplasmic reticulum, and these are known as microsomes (Pearce et al., 1996; De Graaf 
et al., 2002). Microsomes are therefore useful for the in vitro study of phase 1 metabolism 
(De Graaf et al., 2002). An advantage of using microsomes is that they are commercially 
available (from various animal species as well as humans) and can be easily preserved for 
long periods of time through storage at low temperatures (e.g., -80°C) (Wrighton et al., 
1995; De Graaf et al., 2002; Jia and Liu, 2007). In vitro microsomal studies are advantageous 
over in vivo studies when determining the metabolites of a specific substrate since they 
normally result in a more concentrated, cleaner extract for analysis (Scarth et al., 2010).  A 
disadvantage is that microsomes are not able to fully predict in vivo metabolism since they 
do not allow for phase 2 metabolism to occur (De Graaf et al., 2002). This is because they 
only posses UDP-glucuronyltransferases but lack the cofactor UDPGA and any other phase II 
enzymes and cofactors (De Graaf et al., 2002).  
 
This chapter encompasses the use of human liver microsomes for the in vitro phase 1 
metabolism of EPA, DHA and AA. A gas chromatography (GC) method was developed for the 
qualification of these PUFAs and their metabolites. This method was validated in terms of 
inter- and intra-day reproducibility, linearity and limit of detection (LOD). The microsomal 
system was optimised in terms of microsome and FA concentration. The concentrations of 
FA used were chosen such that they were high enough to generate detectable amounts of 
metabolite(s), but not so high that toxicity occurs (De Graaf et al., 2002). 
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3.2 Methods and Materials 
3.2.1 Method validation 
EPA, DHA and AA were purchased from Sigma-Aldrich®, Germany (product numbers: 44864; 
D2534; 10931). Solvents used were analytical grade and purchased from Sigma-Aldrich®, 
Germany. The analytical method for the detection of the FAs of interest was validated in 
terms of inter- and intra-day reproducibility, linearity, and LOD. FAs were dissolved in 1 ml 
dichloromethane (DCM) to a range of concentrations and derivatised using a fatty acid 
methyl ester (FAME) synthesis protocol adapted from Budge et al. (2006). Briefly, 3 ml 
Hilditch reagent (1.5% concentrated H2SO4 in MeOH dried over anhydrous Na2SO4) was 
added to samples which were then covered with N2, capped, sealed with teflon tape, 
vortexed and placed at 100°C for 1 hour (vortexed at 30 minutes again to ensure proper 
mixing). Samples were allowed to cool to room temperature. Liquid-liquid extraction was 
performed by addition of 3 ml hexane and 1 ml MilliQ H2O. Samples were vortexed, 
centrifuged at 857 g (Hettich EBA 20 centrifuge) for 5 minutes, and the top layer removed 
and kept. The hexane extraction was repeated an additional two times using 1 ml hexane 
each time. Anhydrous Na2SO4 was added. Samples were evaporated to dryness under N2 
and reconstituted in 100 μl hexane. GC (Agilent 7000 A), coupled to a flame ionization 
detector (FID), was used to analyse the samples. The column utilised was a Zebron
TM
 ZB-
WAX plus capillary GC column (length: 30 m, internal diameter: 0.32 mm, stationary film 
thickness: 0.25 μm) (Phenomenex, USA). Total run time was 40 minutes. Splitless injection 
was used with an injection temperature of 250°C. Initial oven temperature was 70°C and 
was held for 1 minute. The temperature was ramped at 40°C/minute to 170°C and then at 
2.5°C/minute to 250°C and held for 4.5 minutes. Detection temperature was 300°C. For the 
inter- and intra-day reproducibility studies, the FAs were diluted such that their final 
concentration in the 100 μl hexane would be 200 μM. In the linearity studies, the final 
concentrations used were 25, 50, 100, 200, and 400 μM. Eicosadienoic acid (EDA) (Sigma-
Aldrich®, Germany, product number: E3127) was used as an internal standard (IS) and was 
diluted such that its final concentration was 200 μM. The LODs were determined from linear 
regression curves of average peak height. The concentration at which a signal three times 
the baseline noise would be produced was taken to be the LOD. 
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3.2.2 Derivatisation and extraction optimisation 
3.2.2.1 Derivatisation using 10% H2SO4/MeOH (v/v). 
EPA was used for the optimisation of the derivatisation and extraction process. Microsomal 
incubation mixtures (1 ml) were set up containing 0.3 mg microsomes (Sigma-Aldrich®, 
Germany, product number: M0317), 50 μM EPA, 0.12 M potassium phosphate buffer (pH 
7.4, with 5 mM MgCl2), 5 mM glucose-6-phosphate (G6P) and 1 U/ml glucose-6-phosphate 
dehydrogenase (G6PDH). NADP
+
 was omitted to prevent metabolism from occurring during 
this optimisation assay. G6P, G6PDH and NADP
+
 were purchased from Calbiochem®. Two 
controls were set in place, one lacking microsomes and the other lacking EPA. A third 
control was also set up containing 50 μM EPA in DCM alone. Samples were incubated at 
37°C for 15 minutes after which time 3 ml of a 10% H2SO4/MeOH (v/v) dried over anhydrous 
Na2SO4 solution was added. Samples were then capped with N2, sealed with Teflon tape, 
vortexed and incubated at 100°C for 1 hour (vortexing again at 30 minutes). Samples were 
extracted into hexane and analysed by gas chromatography coupled to a flame ionisation 
detector (GC-FID) as described in section 3.2.1.  
 
3.2.2.2 Optimisation to reduce contaminants 
The assay was repeated, but this time 125 μl of a 0.2% H2SO4/MeOH (v/v) solution was 
added at the end of the 15 minutes incubation period at 37°C instead of the 10% 
H2SO4/MeOH (v/v) solution. Samples were extracted into DCM twice (2 ml DCM used for 
each extraction). The DCM was dried down under N2 to a volume of 1.5 ml and 3 ml Hilditch 
reagent was added. Samples were capped with N2, sealed with teflon tape, vortexed and 
placed at 100°C for 1 hour (vortexed at 30 minutes again to ensure proper mixing). Samples 
were cooled to room temperature, extracted into hexane and analysed via GC-FID as 
described in section 3.2.1.  
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3.2.3 Human liver microsomal system optimisation and PUFA metabolism 
3.2.3.1 Identification of contaminating peaks 
Incubation mixtures were set up in triplicate containing 0.3 mg/ml microsomes, 0.12 M 
potassium phosphate buffer (pH 7.4, with 5 mM MgCl2), 5 mM G6P, 1 U/ml G6PDH and        
1 mM NADP
+
. These mixtures lacked any added FAs. Controls lacking microsomes were also 
prepared. Samples were derivatised through FAME synthesis using 10% H2SO4/MeOH (v/v) 
and extracted three times into hexane as previously described (section 3.2.1). An Agilent 
7000 A GC-MS-QQQ coupled with the NIST 08 MS library was used to analyse the samples. 
The GC-MS running conditions were the same as those stipulated for GC-FID in section 3.2.1. 
MS was conducted in full scan mode using a transfer line temperature of 280°C and EI of 70 
eV. GC-MS peaks were identified using MassHunter (Agilent Technologies).  
 
3.2.3.2 In vitro metabolism of EPA using human liver microsomes  
EPA was used for the optimisation of the human liver microsomal system. The in vitro 
metabolism conditions were adapted from Amet et al. (2002). Incubation mixtures (1 ml) 
were set up containing 0.3 mg microsomes, 50 μM EPA, 0.12 M potassium phosphate buffer 
(pH 7.4, with 5 mM MgCl2), 5 mM G6P, 1 U/ml G6PDH and 1 mM NADP
+
 (added to start the 
reaction). LA was used as a positive control. Three negative controls were established, one 
lacking microsomes and containing EPA, one lacking microsomes and containing LA, and the 
third containing microsomes and lacking FAs. The reaction was carried out for 15 minutes at 
37°C and terminated by the addition of 3 ml 10% H2SO4/MeOH (v/v) dried over anhydrous 
Na2SO4. Derivatisation, extraction into hexane and GC-FID analysis were carried out as 
outlined in section 3.2.1. Samples were also analysed using GC-MS under the same 
conditions stipulated in section 3.2.3.1. GC-MS peaks were analysed using MassHunter. 
 
3.2.3.3 Optimisation of in vitro metabolism of EPA  
The assay was repeated with an increased microsomal concentration of 0.6 mg/ml and FA 
concentration of 100 μM. EPA metabolism was performed in triplicate. LA was used as a 
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positive control and three negative metabolism controls were set up: one lacking 
microsomes and containing EPA, one lacking microsomes and containing LA, and the third 
containing microsomes and lacking FAs. Derivatisation and extraction into hexane were then 
carried out as outlined in section 3.2.1, but the hexane extraction was only performed twice 
instead of three times. Samples were analysed using GC-MS (under the conditions indicated 
in section 3.2.3.1) and peaks generated were identified using MassHunter.  
 
3.2.3.4 DHA and AA metabolism   
The in vitro metabolism of DHA and AA using human liver microsomes was performed in 
triplicate using the same method as stipulated for the in vitro metabolism of EPA outlined in 
section 3.2.3.3.  
 
3.3 Results 
3.3.1 Method validation 
The analytical method for the detection of LA, EPA, DHA and AA involved derivatisation 
through the generation of FAMEs, liquid-liquid extraction into hexane and detection by GC-
FID. This method was validated in terms of inter- and intra-day reproducibility, linearity, and 
LOD. The standard deviations for the average retention times and peak area ratios for the 
FAs were minimal, indicating that the method for the detection of LA, EPA, DHA and AA 
showed inter-day reproducibility (Table 3.1). For each FA, the average retention times and 
peak area ratios generated on the three consecutive days were similar, indicating that LA, 
EPA, DHA and AA showed intra-day reproducibility (Table 3.1). LA, EPA, DHA and AA resulted 
in a linear increase in average peak area ratio with increasing concentration from 25 to 400 
μM (Figure 3.1). The LODs were defined as the concentration at which a signal three times 
baseline noise would be achieved, and were calculated using linear regression curves 
generated from average peak height (data not shown). The LODs were determined to be 
92.61 nM, 169.52 nM, 131.20 nM and 203.77 nM for LA, EPA, DHA and AA respectively. 
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Table 3.1: Inter- and intra-day reproducibility of the detection of LA, EPA, DHA and AA by GC-FID.  
 
Day Retention time (min) 
Average peak area 
ratio* 
LA
 
1 5.075 ± 0.001 0.349 ± 0.052 
2 5.074 ± 0.001 0.345 ± 0.047 
3 5.074 ± 0.001 0.347 ± 0.045 
E
P
A
 
1 19.896 ± 0.002 0.861 ± 0.047 
2 19.890 ± 0.006 0.870 ± 0.049 
3 19.883 ± 0.013 0.869 ± 0.048 
D
H
A
 
1 25.723 ± 0.005 1.401 ± 0.048 
2 25.718 ± 0.008 1.447 ± 0.048 
3 25.710 ± 0.021 1.444 ± 0.044 
A
A
 
1 20.781 ± 0.029 1.468 ± 0.154 
2 20.751 ± 0.017 1.471 ± 0.151 
3 20.785 ± 0.014 1.468 ± 0.139 
 
FAMEs were synthesised and extracted into hexane. Samples were analysed using GC-FID. The assay was 
performed in triplicate on three consecutive days using 200 μM of the FA of interest and 200 μM EDA as an IS. 
*Average peak area ratio was calculated by taking the average of (FA peak area/EDA peak area). 
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Figure 3.1: LA, EPA, DHA and AA GC-FID linearity.  
EDA (200 μM) was used as an IS. FAMEs were synthesised through the use of Hilditch reagent, extracted into 
hexane and detected by GC-FID. The concentration range used for LA, EPA, DHA and AA was from 25 to 400 
μM. Average peak area ratio was calculated by taking the average of (FA peak area/EDA peak area). Error bars 
indicate the standard deviation of the mean where n=3. A) LA linearity. B) EPA linearity. C) DHA linearity. D) AA 
linearity. 
 
3.3.2 Derivatisation and extraction optimisation 
Using the FAME synthesis protocol, hexane extraction and GC-FID detection method 
outlined in section 3.2.2.1, EPA resulted in a peak at 21.961 minutes in the control 
containing EPA dissolved in DCM (Figure 3.2A). This peak was also present in the total 
incubation mix and the control lacking microsomes but containing EPA (Figure 3.2B). It was 
absent in the control containing microsomes but lacking EPA (Figures 3.2A and B). This 
indicates that the peak represented EPA. When an initial extraction into DCM before FAME 
synthesis was performed, a decrease in peak areas for all the major peaks was observed, 
including EPA (Figure 3.3). 
 
 Figure 3.2: EPA extraction from the human liver microsomal system using 10% H
derivatisation.  
An incubation mix was set up containing 0.3 mg microsomes, 50 μM EPA, 0.12 M potassium phosphate buffer 
(pH 7.4, with 5 mM MgCl2), 5 mM G6P and 1 U/ml G6PDH. 
EPA was derivatised by the addition of 10% H
for 1 h. Liquid-liquid extraction into hexan
Chromatogram produced for the control which contained EPA dissolve
hexane blank (blue). B) Overlay of the chromatogram produced for the control containing microsomes but 
lacking EPA (red) and the control lacking microsomes but containing EPA (blue). 
chromatogram produced for the total incubation mix containing EPA (red) and the control containing 
microsomes but lacking EPA (blue). 
 
 
 
NADP
+
 was omitted so as to prevent metabolism. 
2SO4/MeOH (v/v) to this incubation mix and incubation at 100°C 
e was then carried out followed by GC
d in DCM only (red) overlaid with the 
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2SO4/MeOH (v/v) for 
-FID detection. A) 
C) Overlay of the 
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Figure 3.3: Effect of an initial DCM extraction on microsomal contamination.  
An initial extraction into DCM was performed before FAME synthesis and extraction into hexane. The relative 
percent peak areas for the total incubation mix from the assay lacking an initial DCM extraction (section 
3.2.2.1) and the assay in which an initial DCM extraction was performed before derivatisation are compared 
(section 3.2.2.2). The incubation mixes contained 0.3 mg/ml microsomes; 50 μM EPA; 0.12 M phosphate buffer 
(pH 7.4, with 5 mM MgCl2); 5 mM G6P and 1 U/ml G6PDH. Relative percent peak area was calculated by 
allowing the largest peak (appearing at 9.54 min) to represent 100% and then expressing the other peak areas 
as a percentage relative to this peak.  
 
3.3.3 Human liver microsomal system optimisation and PUFA metabolism 
3.3.3.1 Identification of contaminating peaks 
MassHunter was used to identify the contaminating peaks present in incubation mixes set 
up containing microsomes but lacking any added FAs. The main contaminants were various 
FAs, including EPA, DHA and AA (Table 3.2), with different forms of cholesterol forming 
minor contaminants. 
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Table 3.2: Contaminants from human liver microsomes.  
Retention Time Name Formula Area Sum Percent 
5.552 ± 0.003 Myristic acid, ME C15H30O2 0.96 ± 0.10 
7.347 ± 0.025 Palmitic acid, ME C17H34O2 2.75 ± 0.43 
10.126 ± 0.097 Stearic acid, ME C19H38O2 22.08 ± 1.34 
10.378 ± 0.021 Oleic acid, ME C19H36O2 14.55 ± 0.24 
16.026 ± 0.049 Arachidonic acid, ME C21H34O2 23.43 ± 1.38 
17.377 ± 0.043 Eicosapentaenoic acid, ME C21H32O2 0.77 ± 0.08 
22.982 ± 0.025 Docosahexaenoic acid, ME C23H34O2 9.09 ± 0.50 
 
Incubation mixes were set up containing microsomes but lacking any added FAs. FAME synthesis was 
performed followed by extraction into hexane and analysis by GC-MS and MassHunter. The major 
contaminants found are listed. These contaminants were not present in samples lacking microsomes. Average 
(± S.D.) retention time and area sum percent are given, n = 3. 
 
3.3.3.2 In vitro metabolism of EPA PUFA  
The initial EPA metabolism assay was conducted using 0.3 mg/ml microsomes and 50 μM FA 
in 0.12 M potassium phosphate buffer (pH 7.4, with 5 mM MgCl2) with an NADPH 
generating system. The positive control, LA, produced a peak at 4.646 minutes in the control 
containing LA and lacking microsomes (Figure 3.4A). This peak was also present in the total 
incubation mix containing microsomes and LA, 0.12 M, but absent in the control containing 
microsomes and lacking FAs (Figure 3.4B). Through the use of MassHunter, a possible 
metabolite peak for LA was identified at 13.902 minutes (Figure 3.4B and C). This peak was 
identified as 12-OH-LA. It was absent in both the control containing LA and lacking 
microsomes, as well as the control containing microsomes and lacking FAs. The area sum 
percent for LA and 13-OH-LA in the total incubation mix were 2.41 and 0.25% respectively. 
EPA produced a peak at 18.383 minutes in the control containing EPA and lacking 
microsomes (Figure 3.5A). This peak was also present in the total incubation mix containing 
microsomes and EPA (Figure 3.5B). A peak for EPA was identified in the control containing 
microsomes but lacking FAs, but this peak had a smaller peak area than those samples 
which contained added EPA. No EPA metabolites were identified (Figure 3.5B). 
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EPA metabolism was repeated using an increased concentration of 0.6 mg/ml microsomes 
and 100 μM FAs. LA was identified at 4.488 minutes in the total incubation mix containing 
LA as well as the control containing LA and lacking microsomes. 12-OH-LA was identified at 
13.098 minutes in the total incubation mix containing LA and was absent in both the control 
containing microsomes and lacking FAs and the control lacking microsomes and containing 
LA (Data not shown). The area sum percent for LA and 12-OH-LA in the total incubation mix 
were 1.47 and 0.34% respectively. EPA resulted in a peak at 17.381 ± 0.037 minutes in the 
total incubation mixes containing EPA and the control containing EPA and lacking 
microsomes. This peak was also visible in the control lacking EPA and containing 
microsomes, but it was greatly reduced having a peak area that was 7.35% the size of those 
present in the total incubation mix containing EPA. No peaks were identified that could 
represent EPA metabolites (Data not shown). 
 
 Figure 3.4: Initial in vitro metabolism 
An incubation mix containing 50 μM 
buffer (pH 7.4, with 5 mM MgCl2) with an NADPH generating system. Metabolism was allowed to occur for 15 
min at 37°C and terminated by the addition of 10
followed by extraction into hexane and analysis via GC
microsomes resulted in a peak for LA at 4.636 min. The spectrum for L
chromatogram produced for the total incubation mix containing LA (orange) 
containing microsomes and lacking FAs (blue). LA produced a peak at 4.646 min. 
(highlighted by the arrow) was identified in the total incubation mix, but absent in the control. C
view showing metabolite peak at 13.902 min, identified as 12
an inset.  
of LA.  
LA and 0.3 mg/ml microsomes was set up in 0.12 M potassium phosphate 
% H2SO4/MeOH (v/v). FAME synthesis was carried out 
-MS. A) The control containing LA and lacking 
A is shown as an inset. B) 
is overlaid with 
A peak at 13.902 min 
-OH-LA. The spectrum for this peak is shown as 
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The 
the control 
) Zoomed in 
 Figure 3.5: Initial in vitro metabolism 
An incubation mix containing 50 μM EPA and 0.3 mg/ml microsomes was set up in 0.12 M potassium 
phosphate buffer (pH 7.4, with 5 mM MgCl
occur for 15 min at 37°C and terminated by the addition 
carried out followed by extraction into hexane and analysis via GC
control (Figure 3.4). A) The control containing EPA and lacking microsomes produced a peak for EPA at 18
min. The spectrum for EPA is shown as an inset. B) The chromatogram produced for the total incubation mix 
containing EPA (orange) is overlaid with the control containing microsomes and lacking FAs (blue). EPA 
produced a peak at 18.383 min. No metaboli
 
3.3.3.3 DHA and AA metabolism  
DHA and AA in vitro metabolism were
human liver microsomes and 100 μM FAs
4.427 ± 0.002 minutes in the total incubation mixes containing LA and the control containing 
LA and lacking microsomes. This peak was absent in the control containing microsomes and 
lacking LA. 12-OH-LA was present at 12.661 ± 0.004 min
containing LA, but was absent in the control containing LA and lacking microsomes as well 
as the control lacking LA and containing microsomes
chromatogram can be seen in Figure 3.4
replicate 1 were 1.54 and 0.57%, and for replicate 2 
of EPA.  
2) with an NADPH generating system. Metabolism was allowed to 
of 10% H2SO4/MeOH (v/v). FAME synthesis was 
-MS. LA was used as a positive metabolism 
te peaks for EPA were identified.  
 
 carried out in triplicate through the use of 
. The positive control, LA resulted in a peak at 
utes in the total incubation mi
 (Data not shown, but representative 
). The area sum percent for LA
were 2.98 and 0.18% 
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resulted in a peak at 22.454 ± 0.069 minutes in the three total incubation mix replicates 
containing DHA and the control containing DHA and lacking microsomes (Figure 3.6A and B). 
This peak was also present at 22.440 minutes in the control lacking DHA but containing 
microsomes and had a peak area 68.72% that of the DHA present in the total incubation 
mixes. No peaks that could represent DHA metabolites were identified. AA resulted in a 
peak at 15.651 ± 0.018 minutes in the total incubation mixes containing AA as well as the 
control containing AA and lacking microsomes (Figure 3.6C and D). This peak was also 
present in the control containing microsomes but lacking added AA. The area sum percent 
of AA in the control containing microsomes and lacking AA was 22.02% whilst the average 
area sum percent of the total incubation mixes containing AA was higher, being 27.47 ± 
5.01%. No peaks were identified as AA metabolites. 
 
 
 
 Figure 3.6: In vitro metabolism of DHA and AA.
Incubation mixes contained 100 μM FA (DHA or AA), 0.6 mg/ml microsomes, 0.12 M potassium phosphate 
buffer (pH 7.4, with 5 mM MgCl2), and an NADPH generating system. Metabolism was allowed 
min at 37°C and terminated by the addition of 10% H
followed by extraction into hexane and analysis 
chromatograms for one replicate from eac
microsomes produced a peak for DHA at 22.370 min. The spectrum for DHA is shown as an inset. 
chromatogram produced for the total incubation mix containing DHA (orange) is overlaid wi
containing microsomes and lacking FAs (blue). DHA produced a peak at 22.440 min. No metabolite peaks for 
DHA were identified. C) The control containing AA and lacking microsomes produced a peak for AA at 15.498 
min. The spectrum for AA is shown as an inset. 
containing AA (orange) is overlaid with the control containing microsomes and lacking FAs (blue). AA produced 
a peak at 15.629 min. No metabolite peaks for AA were identified.
 
 
  
2SO4/MeOH (v/v). FAME synthesis was carried out 
by GC-MS. The assay was performed in triplicate. The 
h FA are presented here. A) The control containing DHA and lacking 
D) The chromatogram produced for the total incubation mix 
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3.4 Discussion 
3.4.1 Method validation 
Since the derivatisation of LA, EPA, DHA and AA through FAME synthesis; liquid-liquid 
extraction into hexane and analysis via GC-FID showed good linearity (Figure 3.1) in the 
selected concentration range (0 – 400 μM), and inter- and intra-day reproducibility (Table 
3.1), as well as a LOD below the concentration range at which future experiments would be 
carried out, this method was deemed appropriate for LA, EPA, DHA and AA qualification. 
 
3.4.2 Derivatisation and extraction optimisation 
Numerous contaminating peaks were present in the total incubation mixes. This 
contamination was determined to be of microsomal origin since it was present in all 
samples containing microsomes, but absent in controls that lacked microsomes. In order to 
try and reduce this microsomal contamination, an initial extraction into DCM was 
performed, followed by derivatisation and extraction into hexane. This additional extraction 
step reduced the peak areas of the contaminating peaks, but also reduced the peak area for 
EPA (Figure 3.3). This reduction in peak area could therefore be linked to a loss of 
compounds due to the added extraction rather than a decrease in contaminating peaks 
alone. It was therefore decided to omit the initial DCM extraction in future assays so as to 
avoid loss of possible metabolites which may be present in small quantities. 
 
3.4.3 Human liver microsomal system optimisation and PUFA metabolism 
Contaminating peaks produced by the microsomes were identified using MassHunter. The 
main contaminants were found to be FAs. A concern was that EPA, DHA and AA were all 
found to be part of the microsomal contamination. A study performed by Waskell et al. 
(1982) using liver extracts from five male patients over the age of 45 found that 
polyunsaturated fatty acids comprised 42.6% of the total phospholipids from the liver 
microsomes, with EPA, DHA and AA representing 0.25, 5.75, and 14.6% of the total fatty 
acids respectively. This gives a ratio of EPA:DHA:AA of 1:23:58. The area sum percent for 
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EPA, DHA and AA present in microsomal contamination during this study were found to be 
0.77 ± 0.08; 9.09 ± 0.50 and 23.43 ± 1.38% respectively (Table 3.2). This gives a ratio of 
EPA:DHA:AA of 1:12:30. Although the ratio is lower for this experiment, it still indicates that 
in human liver microsomes, the concentration of AA is greater than that of DHA which in 
turn is greater than that of EPA. Previous studies looking at the in vitro metabolism of FAs 
using microsomal systems have not reported that microsomal FAs are extracted along with 
the FAs being analysed and their metabolites (Amet et al., 2002; Fer et al., 2008a). Amet et 
al. (2002) and Fer et al. (2008a) both performed liquid-liquid extractions after microsomal 
incubations, using di-ethylether and ethyl acetate respectively. They analysed their fractions 
using HPLC-MS rather than GC-MS. This means that they did not need to derivatise their 
samples. It was thought that perhaps the derivatisation step used during this study resulted 
in the break down and release of FAs from the microsomes due to the lowered pH and 
increased temperature. However, an initial liquid-liquid extraction into DCM was unable to 
reduce the microsomal contamination. This implies that microsomal contamination should 
have been seen by Amet et al. (2002) and Fer et al. (2008a) who also performed liquid-liquid 
extractions. 
 
LA is a 12-carbon FA and was chosen as a positive control during the in vitro metabolism 
assays since it has been found to be metabolised by CYPs in human liver microsomes (Clarke 
et al., 1994; Castle et al., 1995; Powel et al., 1996). The microsomal system was optimised in 
terms of protein and FA concentration. Initial metabolism studies conducted utilised 0.3 
mg/ml microsomes and 50 μM FAs (LA or EPA). The in vitro metabolism of LA resulted in a 
peak corresponding to 12-OH-LA being produced in the total incubation mix containing LA 
(Figure 3.4). This peak was absent in the control containing microsomes and lacking LA, as 
well as the control lacking microsomes and containing LA. This indicates that the 12-OH-LA 
was produced through phase 1 CYP metabolism in the human liver microsomal system and 
not through spontaneous degradation or microsomal contamination. It can therefore be 
deduced that the conditions used were conducive to FA metabolism. Previous studies have 
reported 12-OH-LA to be the predominant LA metabolite produced in human liver 
microsomes (Clarke et al., 1994; Powel et al., 1996). The ω-hydroxylation of lauric acid has 
been found to be catalysed by CYPs of the 4A and 2E subfamilies (Clarke et al., 1994), with 
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the principle laurate ω-hydroxylating enzyme expressed in human liver proposed to be 
CYP4A11 (Powel et al., 1996). 
 
EPA produced a peak in the total incubation mix containing EPA as well as the control 
containing EPA and lacking microsomes (Figure 3.5). However, no possible EPA metabolites 
were identified. Due to the low metabolism of LA and the fact that EPA was not 
metabolised, it was decided to increase the microsomal concentration from 0.3 mg/ml to 
0.6 mg/ml and to double the concentration of PUFA used in order to try increase 
metabolism. It was also decided to only perform the hexane extraction twice instead of 
three times. The reason for this was that it was noticed that a white suspension would form 
at the interface between the buffer and hexane in all samples containing microsomes. This 
suspension would however be re-dissolved by the third extraction. Once again, 12-OH-LA 
was identified as a metabolite for LA, but no possible metabolite peaks for EPA were 
identified. The increased microsomal and PUFA concentration resulted in an increase in LA 
metabolism. This was evident since the area sum percent for LA decreased whilst the area 
sum percent for 12-OH-LA increased upon increase in microsomal and FA concentration, 
being 2.41% and 0.25% for LA and 12-OH-LA in the incubation mix containing 0.3 mg/ml 
microsomes and 50 μM LA, and 1.47% and 0.34% for LA and 12-OH-LA in the incubation mix 
containing 0.6 mg/ml microsomes and 100 μM LA. DHA and AA in vitro metabolism were 
therefore conducted using 0.6 mg/ml microsomes and 100 μM PUFA. Performing the 
hexane extraction twice instead of three times reduced the microsomal contamination; 
therefore the hexane extraction was performed twice in future studies.  
 
During the in vitro metabolism of DHA and AA, no metabolite peaks were identified (Figure 
3.6). LA was used as a positive control (in duplicate) and was metabolised to 12-OH-LA. The 
area sum percent for LA and 12-OH-LA for replicate 1 were 1.54 and 0.57%, and for replicate 
2 were 2.98 and 0.18% respectively. Since the LA peak area was smaller in replicate 1 than in 
replicate 2 whilst the 12-OH-LA peak area was larger in replicate 1 than in replicate 2, it is 
evident that LA metabolism took place to a greater extent in replicate 1 than in replicate 2. 
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This was unexpected since the assay parameters were the same in both experiments and so 
it would be expected that a similar degree of metabolism would occur. 
 
Since the ω-hydroxylation of lauric acid has been found to be catalysed by CYPs of the 4A 
family (Clarke et al., 1994), it can be deduced that these enzymes were active in the human 
liver microsomes. CYP4A enzymes exhibit (ω-1)-hydroxylase activities when using EPA and 
DHA as substrates (Arnold et al., 2010). It was therefore expected that possible metabolites 
that would be produced during the in vitro metabolism of EPA and DHA using human liver 
microsomes would be 20-hydroxyeicosapentaenoic acid (20-HEPE) and 22-
hydroxydocosahexaenoic acid (22-HDoHE) respectively. Other possible metabolites for EPA 
and DHA that were anticipated were 17, 18-epoxyeicosatetraenoic acid (17, 18-EpETE) and 
19, 20-epoxydocosapentaenoic acid (19, 20-EpDPE) respectively. The reason for this is that 
the n-3 double bond that distinguishes EPA and DHA from their n-6 counterparts is a 
predominant site of epoxidation for many CYP isoforms, including several members of the 
CYP4A subfamily (Arnold et al., 2010; Konkel and Shunck, 2011). The CYP4A subfamily is a 
major 20- hydroxyeicosatetraenoic acid (20-HETE) producing enzyme subfamily in 
mammals, showing an evident regioselectivity in favour of hydroxylating the terminal 
methyl group during AA metabolism (Arnold et al., 2010). It was therefore expected that the 
in vitro metabolism of AA would result in the formation of 20-HETE, the main AA product of 
CYP4A catalysed reactions (Arnold et al., 2010).  
 
Environmental factors such as drugs, diet, and lifestyle have a considerable influence on the 
expression and activity of CYP enzymes (Glue and Clement, 1999). Levels of the different 
CYP isoforms therefore vary greatly among hepatic microsome samples depending on 
exposure to inducers or inhibitors prior to microsomal preparations (Wrighton et al., 1995). 
Thus, a reason why EPA, DHA and AA were not metabolised may be that the CYP isoforms 
required for their metabolism were not induced prior to microsomal fractionation or were 
present in quantities that were insufficient for metabolism to occur.  
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Other factors resulting in considerable variability in CYP expression include age, gender, race 
and genetic factors (Glue and Clement, 1999). CYP genetic polymorphisms and differences 
in gene regulation result in inter-individual differences in CYP expression (Gonzalez and 
Tukey, 2005), and individuals with genetically low levels of enzyme activity (poor 
metabolizers) have been discovered (Glue and Clement, 1999). Thus, the source from which 
the microsomes were isolated could have had genetic polymorphisms which resulted in 
them being poor metabolizers of FAs.  
 
Conclusion 
An analytical method (GC-FID/MS) was optimised for FA analysis and validated in terms of 
inter- and intra-day reproducibility, linearity and LOD. The human liver microsomal system 
was optimised for FA metabolism in terms of microsomal and FA concentration. The system 
resulted in the metabolism of the positive control, LA, to 12-OH-LA. However, it was unable 
to metabolise EPA, DHA and AA. This may be due to low expression or absence of the CYP 
isoforms responsible for their metabolism. Contamination from the microsomes, mainly in 
the form of FAs, was a confounding factor. It was therefore decided to purchase metabolites 
for future comparative studies, using in silico analysis as a basis for metabolite choice. 
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Chapter Four 
Effect of PUFAs on colon cancer cell viability 
4.1 Introduction 
In vitro studies have previously found a correlation between PUFAs and cancer. EPA and 
DHA have been found to have inhibitory effects on carcinogenesis (Ligo et al., 1997; 
Chamras et al., 2002; Schley et al., 2005; Bougnoux et al., 2010; Lu et al., 2010). The affects 
of AA are controversial, with some studies indicating that it promotes cancer (Schley et al., 
2005; Ligo et al., 1997), some that it has no impact on cancer cell growth (Lu et al., 2010), 
and others that it inhibits carcinoma (Schonberg et al., 2006; Habermann et al., 2009). The 
correlation between PUFAs and colon cancer is of particular interest since diet and nutrition 
have been shown to play an important role in the cause and primary prevention of colon 
carcinoma (Matsuura et al., 2006). EPA, DHA and AA have been found to have inhibitory 
effects on colon carcinoma in vitro (Schonberg et al., 2006; Habermann et al., 2009). SW480 
and SW620 are paired colon carcinoma cell lines. SW480 was established from a primary 
adenocarcinoma of the colon in a 50 year old male whilst SW620 was isolated a year later 
from a metastasis of the same tumor in the lymph node (Leibovitz et al., 1976). These cell 
lines were therefore chosen for this study as it allowed for the comparison of the effect of 
PUFAs on different stages of the same tumor. Studies comparing the effects of EPA, DHA 
and AA on carcinoma to the effects of their CYP metabolites have not been conducted to 
date. This chapter therefore aimed to address this topic in the colon carcinoma cell lines, 
SW480 and SW620. Since the human liver microsomal system was unable to metabolise our 
PUFAs of interest, we decided to move the study forward by purchasing known CYP 
metabolites. The selection of a metabolite was based on knowledge gaps in the literature, in 
silico predictions and availability. The metabolite of choice was 17, 18-
epoxyeicosatetraenoic acid (EpETE), which is formed through the CYP epoxidation of EPA at 
the n-3 double bond.  
 
This chapter describes the assessment of the cytotoxicity of EPA, DHA and AA towards 
SW480 and SW620 cells and aims to compare the cytotoxicity of EPA with its CYP 
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metabolite, 17, 18-EpETE, towards SW480 cells through the use of WST-1 cell viability assay 
and real-time cell analysis. 
 
4.2 Methods  
4.2.1 Cell lines and culture conditions 
The paired colon carcinoma cell lines, SW480 and SW620 (European Collection of Cell 
Cultures, catalogue numbers: 87092801 and 87051203 respectively), were maintained in 
culture at 37°C in complete medium containing Leibovitz’s medium (L-15) (Sigma-Aldrich®, 
Germany) supplemented with 10% (v/v) heat-inactivated foetal calf serum (FCS) (Lonza, 
USA), 1 mM  L-glutamine (Sigma-Aldrich®, Germany), and 100 U/ml penicillin, 100 μg/ml 
streptomycin and 12.5 μg/ml amphotericin (PSA) (Sigma-Aldrich®, Germany). 
 
4.2.2 Effect on cell viability 
Cell viability upon treatment with EPA, DHA and AA (SW480 and SW620 cells) or 17, 18-
EpETE (SW480 cells) was assessed by means of WST-1 assay, according to manufacturer’s 
instructions. The method was validated through the assessment of the interference of the 
compounds of interest with the assay. L-15 media was placed in a 96-well plate (100 μl/well) 
and incubated with a range (0 – 200 μM) of concentrations of sulindac sulfide (SuS), 5-
fluorouracil (5FU), AA, DHA, EPA and 17, 18-EpETE at 37°C for 96 hours. After incubation, 10 
μl WST-1 reagent (Roche, Switzerland) was added to each well and incubated at 37°C for 4 
hours. The absorbance at 440 nm was determined using a Powerwave spectrophotometer 
(BioTek). The assay was performed in triplicate. A spectral absorbance scan (λ: 250 – 900 
nm) was conducted for each compound in triplicate using a concentration of 400 μM 
(dissolved in 100 μl DMSO). SuS, 5FU and DMSO were from Sigma-Aldrich®, Germany. 17, 
18-EpETE was from Cayman Chemical, USA (product number: 50861). For WST-1 assays, 
cells were seeded at 3 000 cells/well in complete medium in a 96-well plate and allowed to 
adhere for 24 hours. Cells were treated with a range of concentrations (0 – 200 μM) of EPA, 
DHA or AA (SW480 and SW620 cells) or 17, 18-EpETE (SW480 cells) and incubated at 37°C 
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for 96 hours. SuS (0 – 200 μM) was used as a positive control and 0.5% DMSO (v/v) was used 
as a vehicle control. After treatment, 10 μl WST-1 reagent was added to each well and 
incubated at 37°C for 4 hours. The absorbance at 440 nm was determined with complete 
medium containing WST-1 reagent used as a blank. Cell viability was normalized and 
expressed as a percent of the maximum response. Average cell viability was plotted against 
log concentration. Each compound was assayed in triplicate in three independent 
experiments during assessment of EPA, DHA and AA. 17, 18-EpETE was assayed in triplicate. 
The EC50 values were determined by non-linear regression and compared using an F test (p = 
0.05) (GraphPad Prism Version 4, GraphPad Software, San Diego California, 
www.graphpad.com). A two-tailed, unpaired t-test (p = 0.05) was performed in order to 
asses if there was a significant difference between the effects of 17, 18-EpETE and EPA at 
each concentration.  
 
4.2.3 Real-time analysis of the effect of EPA and 17, 18-EpETE on cell viability 
The real-time cell analyzer xCELLigence System (Roche, Switzerland) was used to monitor 
cell proliferation rates. SW480 cells were seeded at 12 000 cells/well in complete medium in 
a 96-well plate and incubated at 37°C for 96 hours (until a cell index above 0.7 had been 
reached). Cells were treated with a range of EPA and 17, 18-EpETE concentrations (0 – 100 
μM) and incubated at 37°C for 96 hours. SuS (0 – 100 μM) and 5FU (627.1 μM) were used as 
positive controls and 0.5% DMSO was used as a vehicle control. The assay was performed in 
triplicate. One-way ANOVA followed by a Tukey multiple comparisons test was performed 
to assess the variance between treatments (p = 0.05). Microelectronic plates (E-Plates) 
integrated with gold microelectrode arrays were employed during real-time cell analysis 
using the xCELLigence System. Low AC voltage was applied to the plate and produced a 
small electric field between the electrodes, which was impeded by the presence of adherent 
cells (Abassi et al., 2009).  
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Measured cell-electrode impedance was converted to a parameter termed cell index (CI) 
according to the following equation (RTCA software 1.2. Roche, Switzerland): 
CI = ,….
(
(
(
−  1) 
where Rb(f) and Rcell(f) are the frequency-dependent electrode resistances (a component of 
impedance) without cells or with cells present, respectively (Abassi et al., 2009). N is the 
number of the frequency points at which the impedance is measured (Abassi et al., 2009). 
Under the same physiological conditions, the Rcell(f) value increases with increasing cell 
attachment, leading to an increase in the value for CI (Abassi et al., 2009). Decrease in CI 
correlates generally well to cell death (Gerets et al., 2012). 
 
4.3 Results 
4.3.1 WST-1 method validation 
When increasing concentrations of SuS, 5FU, AA, EPA, DHA and 17, 18-EpETE were 
incubated with WST-1 in the absence of cells there was no change in the absorbance at 440 
nm (Figure 4.1). This suggested that the compounds did not react with WST-1 reagent to 
produce a product that absorbed light at 440 nm. A spectral absorbance scan of solutions of 
the compounds indicated that these compounds did not absorb light at 440 nm, but were 
found to absorb light in the UV range as indicated by the peak absorbance between 200 and 
300 nm (Figure 4.1). SuS also resulted in a peak in absorbance between 300 and 400 nm, 
however this was below the 440 nm used for WST-1 assays. Therefore, the WST-1 assay was 
deemed a suitable assay to assess cell viability of SW480 and SW620 cells upon treatment 
with the PUFAs, using SuS and 5FU as positive controls. The media did however absorb light 
at this wavelength, having an average absorbance of 0.189 ± 0.016 (Figure 4.1). Complete 
medium containing WST-1 was therefore used as a blank in future WST-1 assays. 
 
 Figure 4.1: WST-1 method validation.
A range (0 – 200 μM) of SuS, 5FU, AA, DHA, EPA and 
96 h. WST-1 reagent (10 μl) was adde
Average absorbance at 400 nm wa
of the mean where n = 3. A spectral scan (λ: 250 
concentration of 400 μM. Average absorbance 
bars indicate the standard deviation of the mean where 
 
 
17, 18-EpETE concentrations were incubated at 37
d to each well, incubated at 37°C for 4 h, and absorbance read at 440 nm. 
s plotted against concentration. Error bars indicate the standard deviation 
– 900 nm) for each compound was performed 
was plotted against wavelength and shown as an inset
n = 3. 
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4.3.2 Effect of EPA, DHA and AA on SW480 and SW620 cell viability 
SW480 and SW620 cells were incubated with a range (0 – 200 μM) of concentrations of EPA, 
DHA and AA for 96 hours at 37°C. The average percentage cell viability of SW480 (Figure 4.2) 
and SW620 (Figure 4.3) cells was found to decrease with increasing concentrations of these 
PUFAs. This suggested that EPA, DHA and AA reduced SW480 and SW620 cell viability in a 
concentration dependant manner. The EC50 values for EPA, DHA and AA in SW480 cells were 
found to be similar (F test, p > 0.05), being 60.49 μM, 49.12 μM and 49.31 μM respectively. 
The EC50 values for EPA, DHA and AA in SW620 cells were found to be significantly different 
(F test, p < 0.05), being 62.41 μM, 45.54 μM and 36.23 μM respectively. Between cell lines, 
the EC50 values for EPA and DHA were not significantly different (F test, p > 0.05), whilst the 
EC50 value for AA was significantly lower in SW620 cells than in SW480 cells (F test, p < 0.05). 
The positive control, SuS, resulted in an EC50 value of 61.65 μM in SW480 cells and 60.12 μM 
in SW620 cells. 
 
Figure 4.2:  Effect of EPA, DHA and AA on SW480 cell viability.  
SW480 cells were seeded at 3 000 cells/well in a 96-well plate. Viability was assessed via WST-1 assay after 
treatment with a range (0 – 200 μM) of EPA, DHA and AA concentrations for 96 h. Cell viability was normalized 
and expressed as a percent of the maximum response. Average cell viability was plotted against log 
concentration. Error bars indicate the standard deviation of the mean where n = 9. A sigmoidal dose-response 
curve (variable slope) was fitted using GraphPad. An F test (p > 0.05) indicated that the EC50 values for AA, EPA 
and DHA were not significantly different. 
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Figure 4.3:  Effect of EPA, DHA and AA on SW620 cell viability.  
SW620 cells were seeded at 3 000 cells/well in a 96-well plate. Viability was assessed via WST-1 assay after 
treatment with a range (0 – 200 μM) of EPA, DHA and AA concentrations for 96 h. Average cell viability was 
plotted against log concentration. Error bars indicate the standard deviation of the mean where n = 9. A 
sigmoidal dose-response curve (variable slope) was fitted using GraphPad. An F test (p < 0.05) indicated that 
the EC50 values for AA, EPA and DHA were significantly different from each other. 
 
 4.3.3 Effect of 17, 18-EpETE on SW480 cell viability 
SW480 cells were incubated with a range (0 – 200 μM) of 17, 18-EpETE concentrations for 
96 hours at 37°C. A decrease in average percentage cell viability was observed with 
increasing 17, 18-EpETE concentrations (Figure 4.4). This suggested that 17,18-EpETE 
reduced SW480 cell viability in a concentration dependant manner. The EC50 value was 
determined to be 23.23 μM. This EC50 value for 17, 18-EpETE was significantly different to 
the EC50 determined for EPA previously (60.49 μM) (F test, p < 0.05). A two-tailed, unpaired 
t-test showed that the reduction in SW480 cell viability by 17, 18-EpETE and EPA was 
significantly different at both the 25 μM and 50 μM concentrations (p < 0.05).  
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Figure 4.4: Comparison of the effect of EPA and 17, 18-EpETE on SW480 cell viability.  
Cells were seeded at 3 000 cells/well in a 96-well plate. Viability was assessed via WST-1 assay after treatment 
with a range (0 – 200 μM) of 17, 18-EpETE concentrations for 96 h. Cell viability was normalized and expressed 
as a percent of the maximum response. Average cell viability for 17, 18-EpETE was plotted against log 
concentration together with EPA results previously generated for SW480 cells (Figure 4.2). Error bars indicate 
the standard deviation of the mean where n = 3 for 17, 18-EpETE and n = 9 for EPA. A sigmoidal dose-response 
curve (variable slope) was fitted using GraphPad. A two-tailed, unpaired t-test was performed to assess the 
variance between replicates at each concentration using a significance level of p = 0.05. Significant difference 
between EPA and 17, 18-EpETE at a particular concentration is indicated by an asterisk. An F test (p < 0.05) 
indicated that the EC50 values for EPA and 17, 18-EpETE were significantly different. 
 
4.3.4 Real-time analysis of the effect of EPA and 17, 18-EpETE on cell viability 
SW480 cells were treated with a range (0 – 100 μM) of concentrations of EPA and 17, 18-
EpETE for 96 hours. Cells were monitored using the real-time cell analyzer xCELLigence 
System. A decrease in CI over time (from 124.9 – 190.9 hours) was observed for all 
concentrations of EPA and 17, 18-EpETE used (Figure 4.5A). This decrease in CI 
corresponded to an increase in cell death. This suggested that EPA and 17, 18-EpETE 
reduced cell viability of SW480 cells over time. However, the DMSO vehicle control also 
resulted in a decrease in CI, and hence a decrease in SW480 cell viability, over time. The 
average cell death rates for EPA and 17, 18-EpETE were not significantly different to the 
DMSO vehicle control (One-way ANOVA and Tukey multiple comparisons test, p > 0.05) 
(Figure 4.5B). The rate of cell death for 5FU (627.1 μM) was significantly different to the 
DMSO vehicle control (One-way ANOVA and Tukey multiple comparisons test, p < 0.05) 
(Figure 4.5B). 
 Figure 4.5: Real-time analysis of SW480 cells
The real-time cell analyzer xCELLigence System was used to monitor cell proliferation rates. SW480 cells were 
seeded at 12 000 cells/well in a 96-
and 17, 18-EpETE concentrations (0 
normalised against the time just before compound addition
of the mean where n = 3. B) Cell death rates were 
graphs in A (Time 124.9067 – 190.9078 h
One-way ANOVA followed by a Tukey multiple comparisons test was performed to assess the
between treatments (p = 0.05). Significant difference is indicated by an asterisk.  
 treated with EPA and 17, 18-EpETE.
well plate, incubated at 37°C for 96 h and then treated with a range of EPA 
– 100 μM) for 96 h. A) CI over time is reported. 
 (96 h). Error bars indicate the standard deviation 
determined as the gradient from the linear portions of the 
). Error bars indicate the standard deviation of the mean where 
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Each data point was 
n = 3. 
 variance 
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4.4 Discussion 
4.4.1 EPA, DHA and AA reduced SW480 and SW620 cell viability in a concentration 
dependant manner 
SuS resulted in a decrease in SW480 and SW620 cell viability, having an EC50 of 61.65 μM 
and 60.12 μM respectively. Previous studies have also found SuS to be toxic towards colon 
cancer cell lines in the micromolar range, having an EC50 in SW480 and SW620 cells around 
200 ± 110 μM (Chan et al., 1998; Karaguni et al., 2002). 
 
EPA, DHA and AA were found to reduce SW480 (Figure 4.2) and SW620 (Figure 4.3) cell 
viability in a concentration dependent manner, with AA and DHA exhibiting greater 
cytotoxic effects than EPA in both cell lines (Figure 4.2 and 4.3). The effect of AA on 
carcinogenesis is a controversial topic, with some studies reporting it to promote 
carcinogenesis (Ligo et al., 1997; Schley et al., 2005) and others stating that it has inhibitory 
effects on carcinogenesis (Schonberg et al., 2006; Engelbrecht et al., 2008; Habermann et 
al., 2009). EPA, DHA and AA have previously been found to inhibit SW480 and SW620 cell 
viability in a concentration-dependent manner (Schonberg et al., 2006). This concentration-
dependent cytotoxicity has also been reported for EPA, DHA and AA in other colon cancer 
cell lines (Engelbrecht et al., 2008; Habermann et al., 2009). A study by Schonberg et al. 
(2006) found that SW620 cells were more sensitive to EPA, DHA and AA than SW480 cells, 
with DHA exhibiting the strongest effect in both cell lines. They reported cell viabilities of 23, 
50 and 56% in SW480 cells and 5, 25 and 25% in SW620 cells after exposure to 70 μM DHA, 
EPA and AA respectively for 144 hours (Schonberg et al., 2006).  
 
EC50 values for EPA, DHA and AA were in the micromolar range in both cell lines. The EC50 
values for EPA, DHA and AA were not significantly different in SW480 cells (F test, p > 0.05), 
but were significantly different in SW620 cells (F test, p < 0.05). Between cell lines, the EC50 
values for EPA and DHA were not significantly different (F test, p > 0.05), whilst the EC50 
value for AA was significantly lower in SW620 cells than in SW480 cells (F test, p < 0.05). This 
supports previous findings for AA that showed it to be more toxic towards SW620 cells than 
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SW480 cells (Schonberg et al., 2006). EC50 values for EPA, DHA and AA have not been 
previously reported in SW480 and SW620 cells, but have been reported in two other colon 
carcinoma cell lines, namely LT97 and HT29. After treatment with PUFAs for 72 hours, EPA, 
DHA and AA were found to have EC50 values in LT97 cells of approximately 100 μM, 140 μM 
and 110 μM respectively (Habermann et al., 2009). In HT29 cells, EPA, DHA and AA were 
found to have EC50 values of approximately 190 μM, 130 μM and 240 μM (Habermann et al., 
2009). This suggested that EPA, DHA and AA were more toxic towards SW480 and SW620 
cells than LT97 and HT29 cells. However, EPA, DHA and AA cytotoxicity has been found to be 
time-dependent, with greater exposure time resulting in increased toxicity towards cancer 
cell lines (Schonberg et al., 2006; Habermann et al., 2009). Therefore, the decreased 
cytotoxicity seen in LT97 and HT29 cells during the study by Habermann et al. (2009) in 
comparison to the cytotoxicity towards SW480 and SW620 cells observed during this study 
may have been due to a decreased exposure time (72 hours in comparison to 96 hours in 
the current study). Habermann et al. (2009) found the toxicity of AA to be significantly 
different between the two colon cell lines tested. This, together with our findings that AA 
toxicity was significantly different between SW480 and SW620 cells suggested that AA 
toxicity was dependent on the cell line. They also found that the effect of DHA was not 
significantly different between cell lines (Habermann et al., 2009). This, together with our 
findings that DHA toxicity was not significantly different between SW480 and SW620 cells 
suggested that DHA toxicity was not dependent on the cell line. 
 
Blood plasma concentrations of EPA, DHA, and AA have been reported to be 19.4 ± 1.5 
μg/ml, 10.1 ± 0.4 μg/ml and 137 ± 8 μg/ml respectively in subjects consuming a fish-based 
diet (Pawlosky et al., 2003). Since the duodenum is the major site of fat absorption (Besnard 
and Niot, 2000), it is expected that the levels of these PUFAs will be lower in the colon. EC50 
values for EPA, DHA and AA were determined in μM during this study and have been 
converted to μg/ml here for easier comparison. EPA EC50 values determined in this study 
were lower than EPA blood plasma levels, being 18.30 μg/ml (60.49 μM) and 18.88 μg/ml 
(62.41 μM) in SW480 and SW620 cells respectively. AA EC50 values were also lower than AA 
blood plasma levels, being 15.01 μg/ml (49.31 μM) and 11.03 μg/ml (36.23 μM) in SW480 
and SW620 cells respectively. However, DHA EC50 values were higher than DHA blood 
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plasma levels, being 16.14 μg/ml (49.12 μM) and 14.96 μg/ml (45.54 μM) in SW480 and 
SW620 cells respectively, thus suggesting that the DHA concentration required for effective 
inhibition of colon carcinoma will not be reached on a physiological level.  
 
4.4.2 Comparison of toxicity of EPA and 17, 18-EpETE in SW480 cells 
The human liver microsomal system was unable to metabolise our PUFAs of interest, 
therefore we decided to move the study forward by purchasing known CYP metabolites. 
Metabolite selection was based on knowledge gaps in the literature, in silico predictions and 
availability. The metabolite of choice was 17, 18-EpETE, which is formed through the CYP 
epoxidation of EPA at the n-3 double bond. The reasons why an EPA epoxide, and 
specifically 17, 18-EpETE, was chosen were as follows. Firstly, CYP epoxygenases have been 
found to be upregulated in human tumors (Xu et al., 2011). Secondly, EPA showed lower 
toxicity towards both cell lines (Figure 4.2 and 4.3) in comparison to DHA and AA and 
epoxides tend to be more toxic than their parent compounds (Born et al., 1997). Thirdly, 17, 
18-EpETE was ranked, by MetaSite during the in silico analysis (Table 2.2, EPA metabolite 
12), as the most likely EPA epoxide to form during phase 1 CYP-mediated metabolism of 
EPA. Fourthly, the n-3 double bond distinguishes ω-3 FAs from their ω-6 counterparts and is 
known to be a predominant site of epoxidation for many CYP isoforms, including several 
members of the CYP4A subfamily (Arnold et al., 2010; Konkel and Shunck, 2011). Lastly, the 
effects of EPA epoxides on colon carcinoma have not previously been reported. Since EPA 
showed similar toxicity towards SW480 and SW620 cells (F test, p > 0.05), future 
comparative studies of EPA and 17, 18-EpETE were conducted in one cell line only. SW480 
was the cell line of choice since it was isolated from the primary tumor (Leibovitz et al., 
1976).  
 
WST-1 analysis found that 17, 18-EpETE reduced SW480 cell viability in a concentration 
dependant manner, resulting in a significantly greater decrease in SW480 cell viability than 
EPA at a concentration of 25 μM and 50 μM (Figure 4.4) (T-test, p < 0.05). The EC50 for 17, 
18-EpETE (23.23 μM) was significantly lower than the EC50 previously determined for EPA 
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(60.49 μM) in SW480 cells (F test, p < 0.05). The increased toxicity seen for 17, 18-EpETE was 
anticipated since epoxides have been known to be more reactive and toxic than their parent 
compounds (Born et al., 1997). Many toxic epoxides mediate their effects through direct 
interaction of the epoxide moiety with cellular components (Born et al., 1997).  
 
Real-time analysis found that all concentrations of EPA and 17, 18-EpETE (25, 50 and 100 
μM) used resulted in a decrease in CI over time (Figure 4.5A). This decrease in CI can be 
correlated to an increase in cell death. The vehicle control also resulted in a decrease in CI 
over time. The decrease in cell viability observed in the vehicle control may be due to the 
length of the assay. Cells were seeded at 12 000 cells/well in a 96-well plate and incubated 
for 96 hours before compound addition, and then a further 96 hours after compound 
addition. Thus, cells may have become over confluent during this time, leading to cell death, 
or perhaps the nutrients required for growth were depleted during this time since the 
media was not changed (only 50 μl media was added to the original 150 μl media upon 
compound addition).  
 
4.5 Conclusion 
EPA, DHA and AA were found to reduce SW480 and SW620 cell viability in a concentration 
dependent manner. EC50 values for all three PUFAs were in the micromolar range for both 
cell lines, with EPA having a higher EC50 value in both cell lines in comparison to DHA and 
AA.  
 
SW480 cell viability was reduced in a concentration dependant manner upon treatment 
with 17, 18-EpETE. The metabolite, 17, 18-EpETE, was found to be significantly more toxic 
towards SW480 cells than the parent compound, EPA. Since a significant difference in 
cytotoxicity in SW480 cells was observed for EPA and 17, 18-EpETE, the effects of these two 
PUFAs on SW480 cell biology were compared in the forthcoming chapter. This entailed an 
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analysis of the effect of EPA and 17, 18-EpETE on apoptosis, reactive oxygen species (ROS) 
production, cell migration, and anchorage independent growth. 
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Chapter Five 
Comparison of the biological effects of EPA and its CYP metabolite 17, 18-EpETE 
on SW480 cells 
5.1 Introduction 
The ability to evade apoptosis and activate metastasis are two important hallmarks of 
cancer (Jiang et al., 1998; Hanahan and Weinberg, 2011). Cancer cells display unregulated 
growth and are less prone to apoptosis (Jiang et al., 1998). Compounds that lead to 
apoptosis in tumour cells are therefore sought after in cancer prevention and treatment 
(Jiang et al., 1998). EPA has previously been shown to induce apoptosis in cancer cell lines, 
including those of leukemic, pancreatic and colon carcinoma (Chiu and Wan, 1999; Lai et al., 
2006; Giros et al., 2009; Fukui et al., 2013). EPA induced apoptosis has been found to be 
mediated by caspases, with both the intrinsic and extrinsic apoptotic pathways being 
implicated (Giros et al., 2009; Fukui et al., 2013). ROS have been shown to induce apoptosis 
and decrease cell proliferation in cancer cells (Simon et al., 2000; Pelicano et al., 2004). The 
production of ROS has been proposed as a possible mechanism for EPA-induced cell death 
in cancer cells (Field and Schley, 2004; Larsson et al., 2004). This has been supported 
through studies showing that co-treatment with EPA and an antioxidant, such as vitamin E, 
reduces the cytotoxic effects of EPA in vitro and in vivo (Chajès et al., 1995; Latham et al., 
2001; Fukui et al., 2013).  
 
Metastasis is the major cause of mortality in cancer patients (Iwamoto et al., 1998) and 
progression of colon cancer is particularly associated with metastasis formation (Sack et al., 
2011). Thus the suppression of metastasis is an important aspect in the treatment of 
colorectal cancer. EPA has been found to inhibit colon carcinoma metastasis in vivo and in 
vitro (Iwamoto et al., 1998; Hawcroft et al., 2012). In a mouse model of MDA-MB-231 
human breast cancer cell metastasis to bone, a fish oil diet enriched in EPA and DHA has 
been found to inhibit breast cancer cell metastasis to bone (Mandal et al., 2010).  
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Anoikis resistance, or survival in the absence of attachment to extracellular marix, is a 
prerequisite for the development of tumor metastases (Kim et al., 2012). The study of a 
compounds ability to reduce anoikis resistance is therefore important since it encompasses 
the eradication of circulating tumor cells and the prevention of tumor metastasis. 
Anchorage-independent in vitro cell growth is the ability of cancer cells to form colonies 
under conditions that don’t allow for cell adhesion, such as culture in semisolid media (Mori 
et al., 2009). Anchorage-independent cell growth is considered to be fundamental in cancer 
biology since it has been found to be linked to in vivo tumor cell aggressiveness (including 
tumorigenic and metastatic potentials), and has been used as a marker for in vitro 
transformation (Mori et al., 2009).  
 
This chapter aimed to compare the effects of EPA and its CYP metabolite, 17, 18-EpETE, on 
apoptosis, ROS production, and two important components of metastasis, namely, 
migration and anchorage independent cell growth in SW480 cells. The doses used and 
choice of assays were selected based on the previous cytotoxicity assays and the amount of 
compound available. 
 
5.2 Methods 
5.2.1 Detection of apoptosis in EPA and 17, 18-EpETE treated cells 
Annexin V apoptosis detection kit: sc-4252 AK (Santa Cruz) was used for the apoptosis assay 
and the method was adapted from Xie et al. (2011). SW480 cells were seeded at a 
concentration of 7.6 × 10
5
 cells/well into a 24 well plate and allowed to adhere overnight. 
Cells were treated with 25 μM EPA or 25 μM 17, 18-EpETE and incubated at 37°C for 24 
hours. DMSO (0.5 %) was used as a vehicle control and 5FU (5 mM) was used as a positive 
control. After 24 hours, media with floating cells was collected. Adherent cells were washed 
with phosphate buffered saline (PBS) and detached with ACCUTASE (Sigma-Aldrich®, 
Germany). Collected media containing floating cells was added to quench ACCUTASE. Cells 
were harvested by centrifugation (1 125 g for 5 minutes) and resuspended in single cell 
suspension in 1 × assay buffer (catalogue number: sc-4252 AK, Santa Cruz) at a 
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concentration of 1 × 10
6
 cells/100 μl. Annexin V-FITC (0.5 μg) was added and samples were 
incubated at 4°C in the dark for 1 hour. Cells were washed with 1 ml PBS to remove 
unbound Annexin V, collected by centrifugation (1 125 g for 5 minutes) and resuspended in 
single cell suspension in PBS at a concentration of 1 × 10
6
 cells/100 μl. Propidium iodide (PI) 
(0.25 μg) was added and samples were analysed using a FACSAria II flow cytometer (BD 
Biosciences). A blue laser with an excitation wavelength of 488 nm and emission 
wavelengths of 519 nm and 628 nm was used for Annexin V-FITC and PI respectively. The 
following controls were included: untreated and unstained cells; untreated cells stained 
with Annexin V only; untreated cells stained with PI only; untreated cells permeabilized with 
Triton X-100 and stained with PI only. The assay was performed in triplicate. FlowJo 
software (TreeStar Inc.) was used for data analysis. 
 
5.2.2 Effect of EPA and 17, 18-EpETE on reactive oxygen species (ROS) production in SW480 
cells 
The detection of ROS production in treated SW480 cells was adapted from de la Mare et al. 
(2012). SW480 cells were seeded into a black-walled, glass bottom 96 well plate (1 × 10
4
 
cells/well) and allowed to adhere overnight. Cells were treated with 0.5% DMSO (vehicle 
control), or 25, 50, or 100 μM EPA or EpETE and incubated at 37°C for 24 hours.  Cells were 
washed twice with PBS and 100 μM 2’, 7’-dichlorofluorescein diacetate (DCFH-DA) was 
added. DCFH-DA is deacetylated by esterase in the cytosol to produce DCFH, which then 
undergoes ROS-mediated oxidation to form the fluorescent species, DCF (Wu et al., 2010). 
Fluorescence acquisition (Ex: λ485/Em: λ535 nm) was carried out every 10 minutes for 2 
hours in a plate reader (BioTek) at 37°C. Intracellular ROS levels were calculated using the 
following equation: 
F = [(F120 – Fi)/F120 × 100] 
where F120 represents the fluorescence at 120 minutes and Fi represents the initial 
fluorescence at time zero. The addition of 100 μM H2O2 to untreated cells at time zero 
served as a positive control. The experiment was carried out in triplicate. One-way ANOVA 
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(p = 0.05) was performed followed by a Tukey multiple comparisons test (p = 0.05) in order 
to assess if there was a significant difference in intracellular ROS levels. 
 
5.2.3 Effect of EPA and 17, 18-EpETE on SW480 cell migration 
SW480 cell migration was monitored by wound healing assay using a protocol adapted from 
Sade et al. (2012). Rat collagen (100 μg/ml) was used to coat the bottom of wells in a 96-
well plate. SW480 cells were seeded at 1 × 10
6
 cells/well in complete medium and allowed 
to adhere for 24 hours such that a confluent monolayer was formed. The monolayer of cells 
was scratched with a sterile toothpick and debris removed by washing twice with sterile 
PBS. Cells were incubated for 12 hours at 37°C in complete medium containing 25 μM EPA 
or 17, 18-EpETE. DMSO (0.5%) was used as a vehicle control and 5FU (600 μM) was used as 
a positive control. The progress of wound healing was monitored with microphotographs of 
×5 magnification taken at 0, 6 and 12 hours with the Zeiss Axio Vert.A1 microscope. Wound 
area was calculated using ImageJ software and normalised against wound area at 0 hours 
which represented 100%. One-way ANOVA (p = 0.05) was performed followed by a Tukey 
multiple comparisons test (p = 0.05) in order to assess if there was a significant difference in 
migration between treated and vehicle control cells. 
 
5.2.4 Effect of EPA and 17, 18-EpETE on anchorage-independent cell growth in SW480 cells 
5.2.4.1 Soft agar assay 
The method for assessing the effect of EPA and 17, 18-EpETE on SW480 anchorage-
independent cell growth by soft agar assay was adapted from Dhawan et al. (2005). Base 
layers of 100 μl of 0.6% (w/v) agar (Sigma-Aldrich®, Germany) in complete Roswell Park 
Memorial Institute medium (RPMI) (Sigma-Aldrich®, Germany) containing 10% FCS and 100 
U/ml penicillin, 100 μg/ml streptomycin and 12.5 μg/ml amphotericin (PSA) were prepared 
in 96-well plates. After the base layer had solidified, a 100 μl top layer was applied. This 
consisted of 0.3% (w/v) agar in complete RPMI and SW480 cells in single cell suspension at a 
concentration of 500 cells/well. Once this top layer had solidified, 50 μl complete RPMI and 
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an appropriate concentration of test compound was added to each well. EPA and 17, 18-
EpETE were tested at a concentration of 25 μM. DMSO (0.5%) was used as a vehicle control 
and 5FU (600 μM) was used as a positive control. The plate was incubated at 37°C with 9% 
CO2 for 24 days. Cells were given fresh complete RPMI every 4 days (50 μl/well), with half 
the cells receiving complete RPMI alone and the other half receiving complete RPMI 
containing test compounds. Microphotographs of ×10 magnification were taken on day 0 
and day 24 with the DSZ5000X inverted biological microscope and the number of colonies 
having a diameter of 50 μm counted on day 24. One-way ANOVA followed by a Tukey 
multiple comparisons test was performed to assess the variance between the DMSO vehicle 
control and cells treated initially with EPA and 17, 18-EpETE (p = 0.05). 
 
5.2.4.2 Tumorsphere assay 
SW480 cells were grown in Dulbecco’s Modified Eagle Medium (DMEM) containing 2% (v/v) 
B-27 supplement, PSA, 10 μg/ml insulin, 20 ng/ml EGF, 20 ng/ml bFGF and 4 ng/ml heparin 
(Sigma-Aldrich®, Germany). Cells were stained with PI and sorted by fluorescence activated 
cell sorting (FACS) on the FACSAria II instrument (BD Biosciences) such that 500 live 
cells/well were seeded in single cell suspension in a 96-well plate with Ultra-low Attachment 
surface (Corning Inc.). Half the samples were treated on day 0 and half were treated on day 
3, with cells not receiving treatment on day 3 being given fresh medium at this timepoint. 
EPA and 17, 18-EpETE were used at a concentration of 25 μM. DMSO (0.5%) was used as a 
vehicle control and 5FU (600 μM) was used as a positive control. The plate was incubated at 
37°C with 9% CO2 for 6 days. Microphotographs of ×10 magnification were taken on day 0, 3 
and 6 with the DSZ5000X inverted biological microscope. WST-1 assay was performed on 
day 6 to assess cell viability. Briefly, 10 μl WST-1 reagent was added to each well and 
incubated at 37°C for 4 hours. The absorbance at 440 nm was determined with complete 
DMEM containing WST-1 reagent used as a blank. Cell viability was normalized and 
expressed as a percent of the DMSO vehicle control which represented 100% viability. The 
number of colonies having a diameter of 100 μm and greater were counted on day 6.   
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5.3 Results 
5.3.1 Analysis of the mechanism of EPA and 17, 18-EpETE mediated cell death 
SW480 cells were treated with 25 μM EPA or 17, 18-EpETE for 24 hours, stained with 
Annexin V-FITC and PI, and analysed by flow cytometry to detect apoptotic cells (Figure 5.1). 
This concentration was used since it was the lowest concentration that resulted in a 
significant difference in cell viability between EPA and 17, 18-EpETE treated cells (Figure 
4.4). For the DMSO control, 2.12% of cells stained Annexin V-/PI+, 5.50% of cells stained 
Annexin V+/PI+ and 0.79% of cells stained Annexin V+/PI-. Treatment with EPA resulted in 
3.94% of cells stained Annexin V-/PI+, 6.01% of cells stained Annexin V+/PI+ and 0.46% of 
cells stained Annexin V+/PI-. Treatment with 17, 18-EpETE resulted in 2.02% of cells stained 
Annexin V-/PI+, 5.77% of cells stained Annexin V+/PI+ and 0.62% of cells stained Annexin 
V+/PI-. Cells stained Annexin V-/PI+ represent necrotic cells, cells stained Annexin V+/PI+ 
represent late apoptotic cells and cells stained Annexin V+/PI- represent early apoptotic 
cells. Since the percentages for EPA and 17, 18-EpETE were similar to the DMSO control, 
treatment with these compounds did not result in an increase in necrotic and apoptotic cells 
under the conditions tested. This trend was similar for all replicates.  Treatment with 5 mM 
5FU resulted in 4.96% of cells stained Annexin V-/PI+, 14.4% of cells stained Annexin V+/PI+ 
and 1.2% of cells stained Annexin V+/PI-. This indicated an increase in necrotic and 
apoptotic cells after 5FU treatment relative to the DMSO control. 
 
 
 
 
 
 
 
 
 Figure 5.1: Apoptosis analysis of SW480 cells 
SW480 cells were seeded at 7.6 × 10
with 25 μM EPA or 17, 18-EpETE for 24 h. DMSO (0.5%) was used as a vehicle control and 5F
used as a positive control. After 24 h, floating and adherent cells were collected
FITC and PI. Analysis was carried out using a FACSAria II flow cytometer and FlowJo software. For the PI 
positive control, cells were permeabilized with Triton X
were set according to the untreated unstained sample. The assay was performed in triplicate. Representative 
graphs from one set of replicates are shown. The same trend was exhibited in all replicates.
(necrotic), Q2: Annexin V+/PI+ (late apoptotic),
treated with EPA and 17, 18-EpETE. 
5
 cells/well in a 24 well plate, allowed to adhere overnight and treated 
 and stained with Annexin V
-100 before staining with PI (no annexin V). The gates 
 Q3: Annexin V+/PI- (early apoptotic), Q4: Annexin V
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U (5 mM) was 
-
 Q1: Annexin V-/PI+ 
-/PI-.
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5.3.2 Effect of EPA and 17, 18-EpETE on ROS production in SW480 cells 
SW480 cells were treated with a range (0 – 100 μM) of concentrations of EPA or 17, 18-
EpETE for 24 hours. ROS production was monitored after this incubation period through the 
ROS dependent conversion of DCFH-DA to the fluorescent species DCF (Wu et al., 2010). 
H2O2 served as a positive control and showed a linear increase in fluorescence with 
increasing time (Figure 5.2A). Fluorescence increased over time for both the DMSO control 
and cells treated with EPA or 17, 18-EpETE (Figure 5.2A). Intracellular ROS levels were 
calculated using the fluorescent values obtained at 120 minutes (Figure 5.2B). All 
concentrations of 17, 18-EpETE, as well as 50 μM and 100 μM EPA, resulted in decreased 
intracellular ROS levels relative to the DMSO control. Intracellular ROS levels were only 
significantly lower than the DMSO control for 25 μM 17, 18-EpETE (One-way ANOVA, Tukey 
multiple comparisons test, p < 0.05). 
 Figure 5.2: Effect of EPA and 17, 18
DCFH-DA was used to assess the formation of ROS in SW480 cells in the presence and absence of EPA and 
18-EpETE. SW480 cells were incubated with a rang
DA was added to a final concentration of 100 μM and ROS production monitored through the formation of 
DCF. Fluorescence readings were taken every 10 min for 2 h using an excitation wavelength of 485
emission wavelength of 535 nm. A) Change in fluorescence over time. Each concentration is plotted on a 
separate graph for clarity. Error bars indicate the standard deviation of the mean where 
ROS levels were calculated using the following equation: [(F
fluorescence at 120 min and Fi represents the initial fluorescence at time zero.
performed followed by a Tukey multiple comparisons test (p = 0.05)
treatments. Significant difference is indicated by an asterisk. 
-EpETE on ROS production in SW480 cells.  
e of concentrations of EPA or 17, 18-
120 – Fi)/F120 × 100], where F
 One-way ANOVA (p = 0.05) was 
 in order to assess the variance between 
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17, 
EpETE for 24 h. DCFH-
 nm and an 
n = 3. B) Intracellular 
120 represents the 
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5.3.3 Effect of EPA and 17, 18-EpETE on SW480 cell migration 
Wounds were created in confluent monolayers of SW480 cells using a sterile toothpick. 
Wound closure was monitored for 12 hours after treatment with 25 μM EPA or 17, 18-EpETE 
with microphotographs taken at 0, 6 and 12 hours (Figure 5.3A). DMSO (0.5%) was used as 
the vehicle control and 5FU (600 μM) was used as a positive control. ImageJ software was 
used to determine wound area, which was normalised against the wound area at time 0 
which represented 100%. A time dependent decrease in percentage wound area from 0 to 
12 hours was seen for the DMSO vehicle control (Figure 5.3B). Treatment with EPA or 17, 
18-EpETE resulted in a decrease in percentage wound area from 0 to 6 hours, with no 
change in percentage wound area between 6 and 12 hours (Figure 5.3B). The decrease in 
percentage wound area between 0 and 12 hours for EPA and 17, 18-EpETE treated cells was 
slightly lower than for the DMSO control. EPA and 17, 18-EpETE therefore resulted in a 
minor decrease in SW480 cell migration, with the effect being more pronounced between 6 
and 12 hours. The decrease in wound area was however not significantly different between 
EPA, 17, 18-EpETE and the DMSO control (One-way ANOVA, Tukey multiple comparisons 
test, p > 0.05). The positive control, 5FU, was used at a concentration previously found to be 
non-toxic to SW480 cells after 24 hours of exposure (data not shown). The decrease in 
wound area between 0 and 12 hours was significantly less in 5FU treated cells than in the 
DMSO control (One-way ANOVA, Tukey multiple comparisons test, p < 0.05). (Figure 5.3B). 
Therefore, 5FU inhibited SW480 cell migration. 
 Figure 5.3: Migration of SW480 cells after treatment with EPA and 17, 18
SW480 cells were seeded at 1 × 10
collagen. A sterile toothpick was used to make a wound in confluent monolayer
treated with 25 μM EPA or 17, 18-
used as a positive control. A) Microphotographs of ×5 magnific
closure. B) Wound area was calculated using ImageJ software and normalised against 
which represented 100%. Error bars indicate the standard deviation of the mean where 
wound area was not significantly different between EPA, 17, 18
ANOVA, Tukey multiple comparisons test, p > 0.05).
between 5FU and the DMSO control over the 12 h incubation period (One
comparisons test, p < 0.05). Significant difference is indicated by an asterisk.
-EpETE.
6
 cells/well in complete medium in 96-well plates 
s of SW480 cells. Cells were 
EpETE. DMSO (0.5%) was used as a vehicle control and 5FU (600 μM) was 
ation taken at 0, 6 and 12 h
the wound area at 0 h
-EpETE and the DMSO control (One
 The reduction in wound area was significantly different 
-way ANOVA, Tukey multiple 
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5.3.4 Effect of EPA and 17, 18-EpETE on anchorage-independent cell growth in SW480 cells 
5.3.4.1 Soft agar assay 
SW480 cells were grown in 0.3% (w/v) agar for 24 days and effect of 25 μM EPA and 17, 18-
EpETE on colony formation assessed. After 24 days, SW480 cells had formed colonies in the 
DMSO vehicle control (7.67 ± 0.47 colonies/500 cells seeded) (Figure 5.4A and B). Initial 
treatment with EPA and 17, 18-EpETE significantly reduced the number of colonies formed 
by day 24, relative to the DMSO vehicle control, with the number of colonies formed being 
1.67 ± 0.47 colonies/500 cells seeded for both EPA and 17, 18-EpETE (One-way ANOVA, 
Tukey multiple comparisons test, p < 0.05) (Figure 5.4B). The reduction in colony formation 
was not significantly different between EPA and 17, 18-EpETE (One-way ANOVA, Tukey 
multiple comparisons test, p > 0.05). Weekly treatment with EPA and 17, 18-EpETE inhibited 
the formation of any colonies (Figure 5.4A and B). Treatment with 5FU (both initially and 
weekly) led to no colonies being formed by day 24 (Figure 5.4A and B). 
 Figure 5.4: Effect of EPA and 17, 18
agar assay.  
Cells were seeded at 500 cells per well into 0.3
17, 18-EpETE. Fresh media was given every 
half receiving media containing test compound. DMSO (0.5%) was used as a vehicle control and 5F
as a negative control. A) Microphotographs
test compounds. Colonies are indicated
dosed initially and weekly. Colonies having a diameter 
the standard deviation of the mean where 
test was performed to assess the variance between the DMSO vehicle control and cells treated initially with 
EPA and 17, 18-EpETE (p = 0.05). Significant difference is indicated by an asterisk.  
               
-EpETE on SW480 anchorage independent cell growth
% (w/v) agar in complete RPMI and treated with 25 μM EPA or 
4 days, with half the samples receiving media alone and the other 
 taken on day 0 and day 24 for samples receiving an initial dose
 with arrows. B) Number of colonies formed after 24 days in samples 
of 50 μm and greater were count
n = 3. One-way ANOVA followed by a Tukey multiple comparisons 
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5.3.4.2 Tumorsphere assay 
SW480 cells were sorted using flow cytometry and live cells seeded in single cell suspension 
at a concentration of 500 cells/well in a 96-well plate. The number of colonies formed by 
day 6 was found to increase with increased cell concentration (Figure 5.5A). EPA treatment 
either on day 0 (tumorsphere seeding) or day 3 (post tumorsphere formation), significantly 
reduced SW480 tumorsphere viability (Figure 5.5B) as well as the number of colonies 
formed (Figure 5.5C) by day 6, relative to the DMSO control (One-way ANOVA, Tukey 
multiple comparisons test, p < 0.05). Treatment with 17, 18-EpETE on day 0 and day 3 
reduced tumorsphere viability (Figure 5.5B) by day 6 relative to the DMSO control, however, 
this reduction was not significantly different (One-way ANOVA, Tukey multiple comparisons 
test, p > 0.05). Treatment with 17, 18-EpETE resulted in a decrease in the number of 
colonies formed (Figure 5.5C) by day 6 relative to the DMSO control, but the decrease was 
only significant for treatment on day 3 (One-way ANOVA, Tukey multiple comparisons test, 
p < 0.05). Colony formation and tumorsphere viability were significantly lower in cells 
treated with EPA on day 0 in comparison to cells treated with 17, 18-EpETE on day 0 (One-
way ANOVA, Tukey multiple comparisons test, p < 0.05). Colony formation and tumorsphere 
viability were similar in cells treated with EPA on day 3 in comparison to cells treated with 
17, 18-EpETE on day 3 (One-way ANOVA, Tukey multiple comparisons test, p > 0.05). An 
observation made was that colonies formed by day 6 were smaller in samples treated with 
EPA or 17, 18-EpETE in comparison to the DMSO control. The colonies were also smaller in 
samples treated with EPA or 17, 18-EpETE on day 0 compared to those treated with EPA or 
17, 18-EpETE on day 3 (Figure 5.5D and E). 5FU treatment on day 0 and day 3 both 
significantly reduced cell viability (Figure 5.5B) relative to the DMSO control (One-way 
ANOVA, Tukey multiple comparisons test, p < 0.05). Treatment with 5FU on day 0 did not 
allow for any colonies to form, whilst treatment on day 3 significantly reduced the number 
of colonies formed relative to the DMSO control (Figure 5.5C) (One-way ANOVA, Tukey 
multiple comparisons test, p < 0.05).  
 Figure 5.5: Effect of EPA and 17, 18
tumorsphere assay. 
Live cells were seeded in single cell suspension 
in a 96-well plate with Ultra-low Attachment surface
25 μM EPA or 17, 18-EpETE. DMSO (0.5%) was u
positive control. Error bars indicate the standard deviation of the mean where 
by a Tukey multiple comparisons test was performed to assess the variance 
and colony number between DMSO and each treatment for cells treated on day 0 and day 3 (p = 0.05). 
Significant difference relative to the DMSO control 
EPA and 17, 18-EpETE is indicated by a hash sign. A) Number of 
number of cells seeded. B) Cell viability on day 6 assessed by WST
100 μm and greater were counted on day 6. 
day 0. E) Microphotographs taken on day 0, 3 and 6 of cells treated on day 3.
 
 
 
 
-EpETE on SW480 anchorage independent cell growth
by FACS at a concentration of 500 cells/well
. Samples were treated at seeding (day 0)
sed as a vehicle control and 5FU (600 μM) was used as a 
n = 6. One
in average percent cell viability 
is indicated by an asterisk. Significant difference between 
colonies formed on day 6 with increasing 
-1 assay. C) Colonies having a diameter of 
D) Microphotographs taken on day 0, 3 and 6 of cells treated on 
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5.4 Discussion 
5.4.1 Apoptosis and ROS production in EPA and 17, 18-EpETE treated cells  
Cancer cells have been found to have increased ROS levels relative to non-cancerous cells 
(Pelicano et al., 2004; Lu et al., 2007). These increased ROS levels have been attributed, in 
part, to oncogenic stimulation, increased metabolic activity, and mitochondrial malfunction 
(Pelicano et al., 2004). The persistent increased oxidative stress in cancer cells stimulates 
cell proliferation, induces genomic instability and promotes mutations (since the ROS serve 
as an endogenous source of DNA-damaging agents) and leads to development of drug 
resistance (Pelicano et al., 2004; Zhang et al., 2008). A decrease in ROS may therefore lead 
to a decrease in cell proliferation rate, but may not necessarily result in cell death or 
apoptosis. Treatment with 17, 18-EpETE at a concentration of 25 μM significantly decreased 
ROS production and cell viability of SW480 cells (Figure 4.4), but did not result in apoptosis 
in these cells over 24 hours. The decreased cell viability may therefore be representative of 
a decreased cell proliferation rate. The differential effects of EPA and 17, 18-EpETE (25 μM) 
on ROS production may account for the significant decrease in cell viability in 17, 18-EpETE 
treated cells compared to EPA treated cells (25 μM) (Figure 4.4) since at this concentration 
17, 18-EpETE was found to significantly reduce ROS levels whilst ROS levels remained 
constant for EPA relative to the DMSO control.  
 
Since cancer cells are under increased intrinsic ROS stress, and ROS are chemically active 
and can inflict cellular damage, cancer cells are vulnerable to further increases in ROS levels 
(Pelicano et al., 2004). Increased ROS levels have been shown to induce apoptosis and 
decrease cell proliferation in many different cell systems under both physiologic and 
pathologic conditions (Simon et al., 2000; Pelicano et al., 2004). The apoptosis inducing 
ability of 17, 18-EpETE in cancer cell lines has not previously been reported in literature. 
Previous studies have shown that EPA induced apoptosis in several colorectal cell lines, 
including SW480 cells (Clarke et al., 1999; Giros et al., 2009). A study by Giros et al. (2009) 
found that treatment of SW480 cells with 60 μM EPA for 24 hours significantly increased the 
number of apoptotic cells relative to the vehicle control. This significant increase in 
apoptosis was also seen in other colorectal cell lines (Caco-2, HT-29, HCT116 and LoVo) 
84 
 
(Giros et al., 2009). Treatment with 50 μM EPA for 24 hours was found to significantly 
increase apoptosis in HT29 colon carcinoma cells (Clarke et al., 1999). Both the intrinsic and 
extrinsic pathways have been implicated in EPA-induced apoptosis through the down-
regulation of X-linked inhibitor of apoptosis protein (XIAP) and FLICE-like inhibitory protein 
(FLIP) respectively (Giros et al., 2009). A study in MCF-7 cells found that incubation with EPA 
(10 μM, 24 hours) did not significantly increase the percent of apoptotic cells relative to the 
vehicle control (Chamras et al., 2002). The concentrations of EPA at which apoptosis 
occurred were greater than the concentration used during this study (and the concentration 
used in the study of MCF-7 cells which showed no increase in apoptosis with EPA 
treatment). 
 
5.4.2 EPA and 17, 18-EpETE reduced SW480 cell migration and anchorage independent 
growth 
EPA and 17, 18-EpETE resulted in a similar reduction in SW480 cell migration relative to the 
DMSO control from 0 to 12 hours, with the greatest reduction being from 6 to 12 hours 
(One-way ANOVA, Tukey multiple comparisons test, p > 0.05). This indicated that the effect 
of these PUFAs on SW480 cell migration was greater after incubation with these PUFAs for 
more than 6 hours and that EPA and 17, 18-EpETE reduced cell migration with the same 
efficacy. The effects of EPA and 17, 18-EpETE on cell migration have not previously been 
reported in SW480 and SW620 cells. The findings in this study support those of previous 
studies which have shown EPA to inhibit cell migration in the micromolar concentration 
range in different cell lines in vitro. M38 mouse colorectal cancer cell migration has been 
shown to be inhibited by EPA in a dose dependent manner (Volpato et al., 2012). In N87 
gastric cancer cells, treatment with EPA (0.5 μM – 5 μM) has been shown to significantly 
inhibit macrophage-activated cell migration (Wu et al., 2012). Treatment with 165 nM EPA 
significantly reduced MDA-MB-231 breast cancer cell migration over 21 hours in vitro 
(Mandal et al., 2010). Previous studies have not, however, reported that the ability of EPA 
to reduce cell migration increases with time, as observed during this study. Another possible 
reason why the effect of EPA and 17, 18-EpETE was greater from 6 to 12 hours could be that 
SW480 cells have a low migration rate (Sabauste et al., 2009), and therefore it may take 
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longer for the effects of the PUFAs to become evident than if they were used to treat a 
highly migratory cell line such as the SW620 cell line (Sabauste et al., 2009).  
 
The effect of EPA and 17, 18-EpETE on SW480 anchorage independent cell growth was 
assessed during this study using two assays, namely, soft-agar and tumorsphere assay. Both 
assays found that treatment with EPA and 17, 18-EpETE at a concentration of 25 μM 
inhibited anchorage independent growth of SW480 cells. Tumorsphere assays differ from 
soft agar assays in that they are serum free. The ability of cancer cells to form anchorage 
independent colonies under serum-free tumorsphere conditions reflects their stem-like 
characteristics (Wang et al., 2010; Zhang et al., 2012). Normally, very few cells within a 
tumor have the capacity to start a new tumor (Erickson and Hubbard, 2010). Those cells that 
are capable of initiating new tumors are known as cancer stem cells (CSCs) and are of great 
interest because they may not be killed by conventional chemotherapies and could be the 
cause of disease recurrence (Erickson and Hubbard, 2010). The ability of a compound to 
target CSCs is therefore of great importance. Tumorsphere assays are often used to isolate 
cancer stem cells (CSCs) in order to characterize them or to assess the effect of compounds 
on the CSC population (Qiang et al., 2009). The ability of EPA and 17, 18-EpETE to reduce 
colony formation under serum free conditions during this study therefore implicates these 
PUFAs as potential CSC targeting agents.  
 
The soft agar assay found that the extent of inhibition was similar for EPA and 17, 18-EpETE 
(Figure 5.4). This was supported by the results obtained for treatment on day 3 during the 
tumorsphere assay which showed that EPA and 17, 18-EpETE reduced colony formation and 
cell viability relative to the DMSO control to a similar extent in SW480 cells (Figure 5.5). 
Colony formation and cell viability was, however, significantly lower in cells treated with EPA 
on day 0 in comparison to cells treated with 17, 18-EpETE on day 0 during the tumorsphere 
assay (One-way ANOVA, Tukey multiple comparisons test, p < 0.05). This suggested that EPA 
prevented colony formation to a greater extent than 17, 18-EpETE if colonies had not 
already formed prior to treatment, but after colonies had formed, treatment with EPA and 
17, 18-EpETE resulted in the same reduction in colony growth. Perhaps a reason why this 
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significant difference was not seen during the soft agar assay was due to the time 
differences between the assays (the soft agar assay was conducted for 24 days whilst the 
tumorsphere assay was conducted for 6 days). The increased exposure time during the soft 
agar assay may have resulted in a loss of significant difference between EPA and 17, 18-
EpETE since the effects of PUFAs have been found to be time dependent (Schonberg et al., 
2006; Habermann et al., 2009). Another possible explanation could be that EPA is more 
effective at targeting CSCs than 17, 18-EpETE, before colony formation, since the significant 
difference between EPA and 17, 18-EpETE was observed under serum free tumorsphere 
conditions.  
 
The effect of 17, 18-EpETE on anchorage-independent cancer cell growth has not previously 
been reported, but EPA has been shown to inhibit anchorage independent growth. A recent 
study conducted by Yang et al. (2012) found that EPA significantly inhibited anchorage 
independent cell proliferation in a concentration dependent manner in SW620 cells relative 
to the vehicle control (10 μM - 70 μM, 3 days). The concentration used during this study was 
within the concentration range used by Yang et al. (2012), therefore supporting their 
findings.  
 
Since migration and anchorage independent growth are important components of 
metastasis (Steeg, 2003), our findings supported previous in vivo and in vitro studies which 
have shown that EPA, in the micromolar range, reduced cancer cell metastasis in a range of 
cancer types. Dietary administration of EPA has been found to reduce metastasis of MC-26 
mouse colorectal cancer cells to the liver in vivo, and inhibit MC-26 migration in a 
concentration (50 – 200 μM) dependant manner in vitro (Hawcroft et al., 2012). A diet high 
in EPA has been found to significantly reduce the number and size of liver metastatic foci of 
rat colon cancer cells, ACL-15, in vivo (Iwamoto et al., 1998). These effects were explained 
by low expression of vascular cell adhesion molecule 1 resulting in decreased tumor cell 
adhesion to the capillary bed, and decreased cell proliferation at the secondary site 
(Iwamoto et al., 1998).  
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5.5 Conclusion 
Treatment with 25 μM EPA and 17, 18-EpETE for 24 hours did not result in apoptosis in 
SW480 cells. EPA (50 μM and 100 μM) and 17, 18-EpETE (25 μM, 50 μM and 100 μM) 
resulted in decreased intracellular ROS levels relative to the DMSO control, with this 
decrease being significant for 25 μM 17, 18-EpETE. SW480 cell migration was inhibited to a 
similar extent by treatment with EPA and 17, 18-EpETE, with the greatest inhibition being 
seen between 6 and 12 hours of treatment. EPA and 17, 18-EpETE reduced colony formation 
and cell viability of SW480 cells under anchorage independent conditions, with this 
reduction in cell viability being significantly greater for EPA than for 17, 18-EpETE in cells 
treated on day 0 of the tumorsphere assay.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Conclusions
6.1 Overview 
This study aimed to assess the effects of EPA, DHA, AA and their CYP metabolites on the 
paired colon carcinoma cell lines, SW480 and SW620. 
employed and results obtained during this study is summarised in Figure 6.1 and
in more detail in the sections that follow.
Figure 6.1: Outline of the scientific method followed and results achieved during this study.
A significant difference between the effect of EPA and 17, 18
between EPA and 17, 18-EPETE is represented in black. A decrease is indicated by a downward arrow.
Chapter Six 
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6.2 In silico predicted metabolites of EPA, DHA and AA were suitable for oral 
administration 
EPA, DHA and AA were metabolised in silico using two software programs, namely MetaSite 
and SMARTCyp. Predicted metabolites included hydroxy-, di-hydroxy- and epoxy-FAs, and 
these metabolites satisfied the criteria of the Ro5, thus making them suitable for oral 
administration (Table 2.1 and 2.2). Future in silico studies could encompass the use of 
computational software programmes that are able to forecast potential toxicity issues. An 
example of such a programme is DEREK (Deductive Estimation of Risk from Existing 
Knowledge) (LHASA Ltd., Leeds, UK) which is a rule-based system that uses known structure-
toxicity relationships and mechanisms to make quantitative predictions about a compound 
(Greene, 2002). Another software programme that may be of interest is OncoLogic 
(LogiChem Inc., USA) which is a rule-based system that is able to predict the carcinogenic 
potential of chemical structures (Greene, 2002). These software programmes would be 
helpful in predicting the potential toxicity and carcinogenicity of EPA, DHA and AA 
metabolites towards non-cancerous tissues. 
 
6.3 GC-MS method for PUFA detection was developed and validated 
A GC-MS method for the detection of EPA, DHA, AA, LA and their CYP-metabolites was 
developed and validated in terms of inter- and intra-day reproducibility, linearity, and LODs 
(Chapter 3). GC is generally the preferred method for the separation and quantification of 
FAs in the form of FAMEs (Amet et al., 2002).  However, this method has some drawbacks 
that need to be taken into account. Firstly, FAMEs may be lost during derivatisation or 
injection due to their volatile nature; secondly, since the conversion of FAs to methyl esters 
requires that the samples be exposed to high temperatures, thermal degradation or 
structural modification of unsaturated FAs is a possibility; lastly, when using FID the FA is 
unable to be recovered for further analysis since it is destroyed (Amet et al., 2002). High 
performance liquid chromatography (HPLC) may provide an alternative method for the 
separation and quantification of PUFAs in future studies. An advantage to the use of HPLC 
would be that PUFAs would not need to be derivatised prior to detection (Amet et al., 2002; 
Fer et al., 2008a).  
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6.4 Human liver microsomal system resulted in the metabolism of LA to 12-OH-LA 
In vitro metabolism through the use of human liver microsomes resulted in the metabolism 
of the positive control, LA, to 12-OH-LA. This indicates that the system was functional. 
However, it was unable to metabolise the longer chained PUFAs EPA, DHA or AA. CYPs have 
large and fluid substrate binding sites, causing them to have slow catalytic rates since they 
are promiscuous in their capacity to bind and metabolise multiple substrates (Gonzalez and 
Tukey, 2005). For this reason, perhaps a longer incubation period would have resulted in 
metabolism. For example, De Graaf et al. (2002) used an incubation period of 2 hours when 
metabolising their drugs of interest.  
 
Options for future work could involve the use of isolated CYP isoforms or the use of 
hepatocytes (Jia and Liu, 2007). The specific CYP isoform of interest, such as the known FA 
metaboliser CYP4A, could be obtained through purification from an appropriate tissue or 
through complementary DNA (cDNA) expression systems (Wrighton et al., 1995). Using 
specific isoforms would only allow for the study of phase 1 metabolism and would 
selectively determine the metabolites formed by the chosen isoforms, thus resulting in a 
metabolite profile that may be substantially different to that seen in vivo (Jia and Liu, 2007). 
The use of hepatocytes, however, would allow for both phase 1 and phase 2 metabolism 
since all the potential metabolic pathways are intact and available, thereby giving a good 
indication of the metabolites that would be produced in vivo (Wrighton et al., 1995; De 
Graaf et al., 2002). Also, the use of hepatocytes would allow for the induction of the 
enzymes necessary for PUFA metabolism upon incubation with these compounds, thereby 
ensuring metabolism would occur (De Graaf et al., 2002). Hepatocytes could therefore also 
be used in order to identify which metabolising enzymes are induced in the presence of our 
PUFAs of interest (Wrighton et al., 1995). In a study performed by De Graaf et al. (2002) 
different in vitro techniques were used to metabolise three unnamed compounds and the 
resulting metabolites were compared to in vivo findings. Their study showed that 
hepatocytes resulted in a greater percent of the parent compound being metabolised in 
comparison to microsomes. It also showed that a compound that was not metabolised by 
the liver microsomes was able to be metabolised through the use of hepatocytes, thus 
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supporting the suggestion of using hepatocytes in future studies. Drawbacks to the use of 
hepatocytes include their phenotypic instability, restricted accessibility and short functional 
period (Nussler et al., 2001; Castell et al., 2006). Transformed human hepatic cell lines are 
more readily available, easier to maintain in culture and remain functionally active for long 
periods of time, and therefore provide an alternative to hepatocytes during in vitro 
metabolism studies (Nussler et al., 2001). However, previous studies have found cell lines to 
be of limited use in metabolism assays since they don’t accurately reflect the metabolic 
potential of their parent cell (Wrighton et al., 1995). For example, expression levels of genes 
coding for CYPs and some important phase II enzymes have been found to be significantly 
different in the hepatic cell line HepG2 in comparison to human liver samples, with activity 
and expression of phase I enzymes reported to be highly significantly lower in HepG2 cells 
(Wilkening et al., 2003). Hepatocytes are therefore the preferred model for in vitro 
metabolism studies. 
 
6.5 EPA, DHA and AA reduced SW480 and SW620 cell viability in a concentration 
dependent manner 
EPA, DHA and AA were found to reduce the cell viability of SW480 (Figure 4.2) and SW620 
(Figure 4.3) cells in a concentration dependent manner, having EC50 values in the 
micromolar range. Previous studies have reported that these PUFAs reduce the cell viability 
of human colon (Engelbrecht et al., 2008; Habermann et al., 2009), breast and lung cancer 
cells in a concentration dependent manner (Bègin et al., 1986). Future studies could 
therefore be extended to include other cell lines. Since the effect of these PUFAs has 
previously been found to be time-dependent (Schonberg et al., 2006; Habermann et al., 
2009), future studies should assess the effect of PUFA exposure time on SW480 and SW620 
cell viability. 
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6.6 SW480 cell viability was significantly lower in 17, 18-EpETE treated cells than EPA 
treated cells 
WST-1 assay showed that treatment with 17, 18-EpETE significantly reduced SW480 cell 
viability in comparison to EPA at lower concentrations, with the EC50 values being 23.23 μM 
and 60.49 μM for 17, 18-EpETE and EPA respectively (Figure 4.4). Real-time analysis found 
that EPA and 17, 18-EpETE reduced SW480 cell viability, however, these reductions were 
not significantly different to the vehicle control (Figure 4.5). Future studies would need to 
optimise the real-time cell viability assay in terms of cell number and treatment time. The 
effect of replacing media with fresh media upon compound addition should also be 
investigated. A confounding factor when using the xCELLigence System to determine 
cytotoxicity is that any change in the cell status, such as a change in morphology, will lead to 
a change in the CI (Gerets et al., 2012) which may be read as cell death. Future studies 
should therefore also monitor cell morphology in order to determine whether cytotoxicity 
results are being skewed by changes in cell morphology. 
 
Intracellular levels of 17, 18-EpETE are tightly regulated and its metabolism occurs relatively 
rapidly (Fleming, 2011). The soluble epoxide hydrolase (sEH) is the most important EpETE-
metabolising enzyme and converts 17, 18-EpETE to 17, 18-dihydroxyeicosatetraenoic acid 
(DHEQ) through the addition of a water molecule (Fleming, 2011) (Figure 6.2). Future 
studies would need to investigate if the increased toxicity seen for 17, 18-EpETE in 
comparison to EPA was due to 17, 18-EpETE itself or its sEH metabolite 17, 18-DHEQ. This 
could be achieved through the use of sEH inhibitors such as 4-[4-(3-adamantan-1-yl-ureido)-
cyclohexyloxy]-benzoicacid (Hwang et al., 2007). It is proposed that sEH inhibition would 
increase 17, 18-EpETE toxicity since epoxides are generally more biologically active than 
their diol metabolites (Fleming, 2011). Future studies involving CYP epoxygenase inhibitors 
such as 17-ODYA (Jiang et al., 2005) would also be of interest in order to determine if the 
cytotoxic effects observed by EPA were due to EPA itself or if EPA was metabolised to 17, 
18-EpETE which then resulted in the observed cytotoxicity. If the latter was the case, it could 
be used to explain the decreased cytotoxicity observed in EPA since EPA would need to be 
metabolised to 17, 18-EpETE before any cytotoxic effects could occur.  
  
Figure 6.2: EPA metabolism. 
EPA is metabolised by cytochrome P450 epoxygenases to 17, 18
corresponding diol by the soluble epoxide hydrolase (sEH). 
Dihydroxyeicosatetraenoic acid. (Adapted from Fleming 2011).
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be detected by flow cytometry (Banks et al., 2011). The CFSE fluorescence intensity (FI) is 
sequentially halved after cell division and therefore provides an indirect measure of the 
number of divisions a cell has undergone (Banks et al., 2011). Up to eight rounds of cell 
division can be monitored before the CFSE FI is reduced to the background flourescence 
level of unstained cells (Banks et al., 2011). 
 
Studies assessing the link between EPA, CYP epoxidation and carcinogenesis have not been 
conducted to date. A study performed by Cui et al. (2011) assessed the effect of four EPA 
epoxides (17,18-, 14,15-, 11,12- and 8,9-EpETE) on the non-cancerous bEND.3 cell line 
established from mouse brain endothelial cells. They did not, however, compare their 
results to the parent compound, EPA. The metabolite, 17, 18-EpETE, significantly inhibited 
bEND.3 cell proliferation, whilst 8, 9- and 11, 12-EpETE stimulated proliferation, and 14, 15-
EpETE had no effect relative to the DMSO control (10 μM, 24 hours) (Cui et al., 2011). These 
differential effects highlight the possible relevance of the ω-3 double bond in EPA which is 
transformed in the production of 17, 18-EpETE.  
 
Jiang et al. (2007) assessed the effects of AA epoxides, epoxyeicosatrienoic acids (EETs), on 
carcinoma; however, their study was limited as they didn’t compare these effects to those 
of the parent compound. CYP2J2 is the predominant human AA epoxygenase that generates 
all four epoxyeicosatrienoic acids (EETs), namely 5,6-; 8, 9-; 11,12-; and 14,15-EET, through 
the addition of an epoxide group to one of the four double bonds of AA  (Jiang et al., 2007; 
Xu et al., 2011). Transfection with a recombinant adeno-associated virus vector containing 
the CYP2J2 cDNA in a sense direction (rAAV-CYP2J2), or addition of exogenous EETs was 
found to increase cell proliferation in eight cancer cell lines (ScaBER, SiHa, U251, A549, Tca-
8113, Ncl-H446, HepG2, and the colon carcinoma cell line LS-174) (Jiang et al., 2005).  
 
The current study was limited to one metabolite due to the high cost and limited 
commercial availability of these metabolites. Another limitation was that only a small 
amount of metabolite was able to be purchased, and therefore the study was carried out on 
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a single cell line. Future studies therefore need to look at the effect of DHA and AA 
epoxides, and should incorporate both SW480 and SW620 cells in order to compare the 
effect of these compounds on the primary tumor and its metastatic counterpart. The effect 
of different PUFA epoxide isoforms should also be investigated to see if the position of 
epoxidation has an effect on function. 
 
6.7 EPA and 17, 18-EpETE did not induce apoptosis in SW480 cells at a concentration of 25 
μM over 24 hours 
At a concentration of 25 μM, EPA and 17, 18-EpETE did not result in apoptosis in SW480 
cells over a 24 hour incubation period (Figure 5.1). This result alone, however, is not 
sufficient to conclude that EPA and 17, 18-EpETE do not induce apoptosis in SW480 cells 
since our study only looked at a single concentration of the PUFAs and a single incubation 
period. Future studies using a range of concentrations therefore need to be performed in 
order to confirm if EPA and 17, 18-EpETE result in apoptosis in SW480 cells at 
concentrations greater than 25 μM and to determine at which concentration apoptotic 
effects begin to be exhibited. The effect of increased incubation time also needs to be 
addressed and the mechanism of apoptosis should be investigated in order to determine if 
the parent compound and metabolite activate the same pathways.  
 
6.8 The EPA epoxide, 17, 18-EpETE, significantly reduced ROS production in SW480 cells 
EPA and 17, 18-EpETE reduced ROS production in SW480 cells, with this reduction being 
significantly different to the vehicle control for cells treated with 25 μM 17, 18-EpETE 
(Figure 5.2). A possible reason why 17, 18-EpETE resulted in a significant reduction in ROS 
whilst EPA did not, could be linked to the enzyme sEH. Since sEH is the main enzyme 
responsible for 17, 18-EpETE metabolism it may possibly be upregulated in 17, 18-EpETE 
treated cells (Fleming, 2011). sEH and microsomal epoxide hydrolases (mEH) belong to the 
same family of C-X bond hydrolases which involve an alkyl-enzyme intermediate 
(Lacourciere and Armstrong, 1994). mEH have been found to participate in the removal of 
reactive oxygen species (Cheong et al., 2009). sEH may therefore be responsible for the 
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significant decrease in ROS in 17, 18-EpETE treated cells. Future studies could test this 
hypothesis through the use of sEH inhibitors such as 1-(1-methanesulfonyl-piperidin-4-yl)-3-
(4-trifluoromethoxy-phenyl)-urea (TUPS) (Aboutabl et al., 2011). 
 
Increased ROS levels have been shown to reduce cell viability and induce apoptosis in many 
different cell systems (Simon et al., 2000; Pelicano et al., 2004), and an increase in ROS has 
been proposed as a mechanism of EPA mediated apoptotic cell death in cancer cells (Fukui 
et al., 2013). Treatment of the pancreatic cell line MIA-PaCa-2 with 100 μM EPA was found 
to increase intracellular ROS accumulation (Fukui et al., 2013). Co-treatment with the 
antioxidant vitamin E and EPA suppressed intracellular ROS accumulation and cell death, 
showing that EPA reduced cell viability in MIA-PaCa-2 cells through the production of ROS 
(Fukui et al., 2013). Treatment of two breast carcinoma cell lines, namely HBL-100 and ZR-
75, with 66 μM EPA was found to significantly decrease cell proliferation and increase the 
concentration of cellular lipid hydroperoxides relative to the vehicle control (Chajès et al., 
1995). Simultaneous addition of vitamin E (10 μM) and EPA resulted in a significant decrease 
of cellular lipid hydroperoxides relative to EPA treated cells as well as a restoration in cell 
proliferation (Chajès et al., 1995). This suggested that the inhibitory effects of EPA on 
proliferation of HBL-100 and ZR-75 cells were linked to the formation of lipid peroxidation 
products. 
 
Prospective studies need to explore the link between ROS, cell viability and apoptosis. This 
could be achieved by assessing the effect of co-treatment with PUFAs and anti-oxidants on 
ROS production, cell viability and apoptosis (Chajès et al., 1995; Fukui et al., 2013). The 
ability of the PUFAs to mop up ROS also needs to be assessed. This could be achieved by 
generating ROS in cells through incubation with 5FU (Zhang et al., 2008) followed by 
incubation with the PUFAs. Future studies should expand the test concentrations to include 
concentrations lower than 25 μM and between 25 μM and 100 μM.  
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6.9 EPA and 17, 18-EpETE reduced SW480 cell migration and anchorage independent 
growth 
The reduction in SW480 cell migration was similar for EPA and 17, 18-EpETE treated cells. 
Future time and concentration studies should be performed to assess if EPA and 17, 18-
EpETE continue to exert similar effects on SW480 cell migration at increased exposure time 
and concentrations. Exposure studies could be achieved by pre-incubating cells with EPA 
and 17, 18-EpETE for different lengths of time before seeding for the wound healing assay. 
Transwell migration assays may also be helpful in future studies. 
 
EPA has been implicated as a potential CSC targeting compound due to its ability to inhibit 
cell proliferation and induce apoptosis under anchorage independent conditions in 
carcinoma cell lines (Chamras et al., 2002; Erickson and Hubbard et al., 2010; Yang et al., 
2012). The current study supported this hypothesis since EPA was found to reduce SW480 
cell growth under serum free tumorsphere conditions (Figure 5.5). A self renewal assay 
performed by Erickson and Hubbard (2010) on PyV-mT breast cancer cells provides further 
evidence to support the hypothesis that EPA is able to target CSC. Primary tumorspheres 
from cultures treated with 5 μM EPA were dissociated and the resultant cells re-cultured 
with 5 μM EPA. EPA was found to significantly reduce the formation of secondary 
tumorspheres relative to the vehicle control and primary tumorspheres (Erickson and 
Hubbard et al., 2010). The reduction in primary and secondary tumorsphere formation 
suggested that EPA may be able to target the tumor initiating CSC subpopulation as well as 
terminally differentiated tumor cells. Further evidence that EPA may be able to target CSCs 
has been provided by a study that found that EPA reduced the expression of CD44 protein, 
as well as CD44 mRNA, in MDA-MB-231 breast cancer cells in vitro and in vivo (Mandal et al., 
2010). CD44 is a cell surface adhesion protein that has been reported to promote the 
progression of cancer metastasis (Weber et al., 2002; Ouhit et al., 2007) and is a putative 
marker of colon and breast CSCs (Lei et al., 2008; Wang et al., 2012). Future studies to 
compare the effect of EPA and 17, 18-EpETE on colon CSCs need to be performed. This could 
be addressed through the use of anchorage independent assays performed using cells that 
are CD44+, sorted by fluorescence-activated cell sorting (FACS). CD133 is also a putative 
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marker of colon CSCs (Wang et al., 2012) and could therefore be used in combination with 
CD44 in order to isolate colon CSCs. The use of self renewal assays would also be a helpful 
tool. 
 
An important consideration to take into account for the anchorage independent growth 
data is that cell viability was not assessed during the soft agar assay but was assessed during 
the tumorsphere assay. Future studies need to conduct a WST-1 assessment of cell viability 
at the end of the soft agar assay and look at the effect of time and PUFA concentration on 
the inhibition of anchorage independent growth by EPA and 17, 18-EpETE in SW480 cells. 
 
Future studies could be expanded to address the effect of EPA and 17, 18-EpETE on 
anchorage independent growth in a range of cancer cell lines as well as their effect on 
apoptosis under anchorage independent conditions. EPA has been found to inhibit 
anchorage independent growth in breast carcinoma. Soft-agar analysis of anchorage-
independent cell growth in MCF-7 breast cancer cells showed that EPA (10 μM and 100μM 
for 14 days) significantly reduced colony formation relative to the vehicle control (Chamras 
et al., 2002). In PyV-mT breast cancer cells, EPA (5 μM treatment for 2 weeks) has been 
shown to significantly reduce the number of tumorspheres formed as well as cell 
proliferation relative to the vehicle control (Erickson and Hubbard et al., 2010). EPA has 
been found to induce apoptosis in SW620 cells grown under anchorage independent 
conditions (Yang et al., 2012).  
 
EPA and 17, 18-EpETE may play a role in the inhibition of cancer metastasis since they were 
able to inhibit two fundamental processes that underpin cancer metastasis, namely cell 
migration and anchorage-independent growth, in SW480 cells during this study. The effects 
of EPA and 17, 18-EpETE on other aspects of metastasis, such as invasion, should be 
compared in SW480 cells in future studies. In vivo animal models would be an important 
tool in assessing the effect on metastasis in future work (Iwamoto et al., 1998; Hawcroft et 
al., 2012). 
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The effect of the AA CYP metabolites, EETs, on metastasis has previously been reported. 
EETs were found to promote metastasis in human breast cancer cell lines (Jiang et. al., 
2007). These findings are limited, however, as the effect of the metabolites was not 
compared with the parent compound. Addition of exogenous EET regioisomers or 
overexpression of CYP2J2 or CYP102 F87V with an associated increase in EET production has 
been found to result in a significant increase in transwell migration and invasion into 
matrigel in human breast cancer cell lines in comparison to untreated cells and vehicle 
controls (Jiang et. al., 2007). Transfection with rAAV-antiCYP2J2 or administration of 17-
ODYA was shown to significantly inhibit the migration and invasion in human breast cancer 
cells (Jiang et. al., 2007). Future studies should look at comparing the effects of DHA and AA 
to the effects of their CYP epoxides on cancer cell metastasis.  
 
6.10 Effects of PUFA on non-cancerous tissues 
The effects of EPA, DHA, AA and 17, 18-EpETE on non-cancerous tissues was not addressed 
in this study and should be looked at in future work. Previous studies have found EPA, DHA 
and AA to be non-toxic towards non-cancerous cell lines. Engelbrecht et al. (2008) looked at 
the effect of various FAs, including AA and DHA, on colon carcinoma cells (CACO2-2) and 
“normal” colon epithelium cells (NCM460). Although AA (10 μM, 48 hours) reduced cell 
viability in CACO-2 cells, this reduction was not significant (Engelbrecht et al., 2008). DHA 
(10 μM, 48 hours), however, significantly reduced the cell viability of CACO-2 cells 
(Engelbrecht et al., 2008). AA and DHA (10 μM, 48 hours) increased cell viability in NCM460 
cells, with this increase being significant for DHA (Engelbrecht et al., 2008). At a 
concentration of 24 μM, EPA, DHA and AA have been found to significantly inhibit growth of 
MCF-7 breast cancer cells, but not MCF-10A non-cancerous human mammary epithelial cells 
(Grammatikos et al., 1994). The incubation periods used were different for the two cell 
lines, being 7 days for MCF-7 and 4 days for MCF-10A. This may have confounded their 
findings since the effects of PUFAs have been found to be time dependent (Schonberg et al., 
2006; Habermann et al., 2009). In terms of ROS production, supplementation with 66 μM 
EPA or DHA in the human breast cancer cell lines HBL-100 and ZR-75 resulted in a significant 
increase in lipid hydroperoxides relative to the vehicle control (Chajès et al., 1995). 
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Supplementation of non-cancerous human skin fibroblasts with EPA or DHA did not increase 
the amount of lipid hydroperoxides (Chajès et al., 1995). Supplementation with DHA and 
EPA did not induce apoptosis in the normal human colon mucosal epithelial cells NCM460 
(Giros et al., 2009).  
 
6.11 Final conclusions 
In conclusion, the dietary intake of EPA, DHA and AA may be beneficial to one’s health due 
to the negative effects that these PUFAs have on colon carcinoma, exhibited by the 
decrease in SW480 and SW620 colon cell viability during this study. Supplementation with 
the EPA metabolite, 17, 18-EpETE, may prove to be more beneficial than the intake of EPA 
since it was found to significantly reduce SW480 cell viability relative to EPA treated cells at 
lower concentrations. However, due to the high cost of the metabolite, this may not be a 
feasible option at present. Since, at lower concentrations, 17, 18-EpETE significantly 
decreased SW480 cell viability relative to EPA, the dietary intake of EPA may have variable 
benefits between individuals due to inter-individual differences in metabolism. Age, gender, 
race and genetic factors considerably influence the expression of CYPs (Glue and Clement, 
1999; Gonzalez and Tukey, 2005), and individuals with low levels of enzyme activity (poor 
metabolisers) would benefit less than individuals that are good metabolisers. EPA and 17, 
18-EpETE were also found to reduce SW480 cell migration and anchorage-independent 
growth, thereby supporting their possible use in colon cancer prevention. Future studies are 
needed in order to further understand the negative effects of PUFAs on carcinoma and to 
determine the mechanisms by which these effects occur. 
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